

Curriculum vitae and Bibliography

GENERAL INFORMATION

Name **Karyn Aalami Goodman, MD, MS, FACR, FASTRO, FASCO**

EDUCATIONAL BACKGROUND

<i>Degree</i>	<i>Institution name and location</i>	<i>Dates attended</i>	<i>Year Awarded</i>
BA, Honors Human Biology	Stanford University, Stanford, CA	1989-93	1993
Research Fellow	Division of Reproductive Health, Centers for Disease Control (CDC), Atlanta, GA	1993	1994
MD	Stanford University, Stanford, CA	1994-99	1999
MS Epidemiology	Harvard School of Public Health Boston, MA	2002-06	2006

APPOINTMENTS/EMPLOYMENT

Post-doctoral training

<i>Title</i>	<i>Institution name and location</i>	<i>Dates</i>
Internship, Internal Medicine	Stanford University, Stanford, CA	7/99-6/00
Residency, Radiation Oncology	Memorial Sloan-Kettering Cancer Center New York, NY	7/00-6/04

Karyn A. Goodman, MD, MS

Academic positions

<i>Title</i>	<i>Institution name and location</i>	<i>Dates</i>
Research Fellow	Division of Reproductive Health, Centers for Disease Control, Atlanta, GA	6/93-9/94
Assistant Professor Radiation Oncology	Stanford University, Stanford, CA	9/04-12/06
Assistant Member Radiation Oncology	Memorial Sloan-Kettering Cancer Center New York, NY	3/07-9/11
Associate Member Radiation Oncology	Memorial Sloan-Kettering Cancer Center New York, NY	10/11-9/15
Professor Radiation Oncology Vice-Chair, Clinical Research	University of Colorado School of Medicine Denver, CO	9/15 - 9/19
Medical Director, Cancer Clinical Trials Office	University of Colorado Cancer Center, Aurora, CO	9/15-9/16
Associate Director of Clinical Research	University of Colorado Cancer Center, Aurora, CO	9/16- 9/19
Professor, Vice Chair Radiation Oncology	Icahn School of Medicine at Mount Sinai	9/19 - present
Professor, Medicine, Division of Hematology and Oncology	Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai	9/19 - present
Associate Director of Clinical Research	Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai	9/19 - present

Hospital positions

<i>Title</i>	<i>Institution name, city and state</i>	<i>Dates</i>
Attending Physician, Radiation Oncology	Stanford University, Stanford, CA	9/04-12/06
Attending Physician, Radiation Oncology	Lucile Packard Children's Hospital Stanford, CA	9/04-12/06
Assistant Attending Radiation Oncologist	Memorial Hospital for Cancer & Allied Diseases, New York, NY	3/07-9/11

Karyn A. Goodman, MD, MS

Associate Attending Radiation Oncologist	Memorial Hospital for Cancer & Allied Diseases, New York, NY	10/11-9/15
Attending Physician, Radiation Oncology,	University of Colorado Hospital, Aurora, CO	9/15- 9/19
Attending Physician, Radiation Oncology	Mount Sinai Hospital, New York, NY	9/19 - Present

GAPS IN EMPLOYMENT

None

CERTIFICATION

<u>Full Name of Board</u>	<u>Certificate #</u>	<u>Date</u>
American Board of Radiology	53542	06/07/05
ABR Maintenance of Certification		06/01/15

HONORS AND AWARDS

<i>Name of award</i>	<i>Date</i>
Cap and Gown Women's Honor Society, Stanford University	1992
Phi Beta Kappa Academic Honor Society, Stanford University	1993
Albert Hastorf Award for Outstanding Service to Human Biology, Stanford University	1993
Scholastic Honors, Stanford University	1993
Medical Scholar, Stanford Medical School	1995
Traveling Medical Scholar, Stanford Medical School	1996
Latin American Studies Travel Grant, Stanford University	1996
Low-Beer Fellowship in Radiation Oncology, UCSF School of Medicine	1998
Norman Blank Award for Outstanding Radiology Research, Stanford University	1999
American Brachytherapy Society Resident Travel Award	2002
AAWR Distinguished Resident in Radiation Oncology Award	2003
ASCO Young Investigator Award	2004

Karyn A. Goodman, MD, MS

Roentgen Resident Research Award	2004
ASTRO Health Services/Outcomes Research Travel Award	2006
AAWR Research & Educational Foundation Professional Leadership Award	2008
Leadership for Innovative Team Science (LITeS) Participant, University of Colorado	2016
Mentorship Award, ASCO/AACR Vail Workshop on Methods in Clinical Cancer Research	2019

PATENTS

Patent No. 10307613: Internal body cavity therapeutic applicator arrangement and methods for using the same.

Filed: February 6, 2017

Date of Patent: June 4, 2019

Inventors: Karyn Goodman, Gil'ad Cohen and Gary Lamoureaux

Developed an endorectal brachytherapy applicator

OTHER PROFESSIONAL ROLES

Elected Memberships in Honor Society

<i>Role</i>	<i>Name of Organization</i>	<i>Dates</i>
Fellow	American College of Radiology (FACR)	2018-
Fellow	American Society of Clinical Oncology (FASCO)	2021-
Fellow	American Society of Therapeutic Radiology and Oncology (FASTRO)	2021-

Editorial Boards

<i>Journal</i>	<i>Dates</i>
Annals of Pancreatic Cancer	2018-
ESMO Gastrointestinal Oncology	2023-

Extramural Service

<i>Role</i>	<i>Name of Organization</i>	<i>Dates</i>
Member	American Society of Therapeutic Radiation and Oncology	2000-
Member	New York Roentgen Society	2000-2015
Member	American Brachytherapy Society	2001-2015
Member	American Association for Women Radiologists (AAWR)	2002-2014

Karyn A. Goodman, MD, MS

Member	Radiological Society of North America	2003-2012
Member	American Society of Clinical Oncology Committee Service:	2003-
	• Life-Long Learning Subcommittee	2008-2011
	• Integrated Media and Technology Committee	2012-2014
	• Scientific Program Committee on the Gastrointestinal (Noncolorectal) Cancer	2012-2014
	• Cancer Research Committee	2014-2016
	• Scientific Program Committee on the Gastrointestinal (Colorectal) Cancer	2017-
Member	Children's Oncology Group	2004-07
Member	American College of Radiology	2004-
Member	American Association for Cancer Research	2004-08
Member	Soft Tissue Sarcoma Committee, Children's Oncology Group	2004-07
Member	Cancer & Leukemia Group B (CALGB)/Alliance for Clinical Trials in Oncology GI Committee	2007-
Member	Radiation Therapy Oncology Group (RTOG)/NRG	2007-
Member	American College of Radiology (ACR) Quality Research in Radiation Oncology (QRRO) GI Committee	2007-2012
Member	National Cancer Institute (NCI) Esophagogastric Task Force	2012-2014
Examiner	American Board of Radiology (ABR) Oral Board Examiner	2011-2021
Study Section Reviewer	SU2C and Farrah Fawcett Foundation Human Papillomavirus (HPV) Translational Research Team Grant	2012-2013
Advisory Board Member	HPV and Anal Cancer Foundation	2012-
	American Society of Therapeutic Radiation and Oncology (ASTRO) Best Practices Subcommittee of the Clinical Affairs and Quality Council	2012-2017
Member	American Joint Committee on Cancer (AJCC) - Staging Chapter for Rectal and Anal Cancers	2014-2016
Study Section Reviewer	Deutsche Forschungsgemeinschaft (DFG) Funding Application for MRI Linear Accelerator for German Academic Institutions (Bonn, Germany)	2015
Member	National Cancer Institute (NCI) Rectal-Anal Task Force	2016-
Member Reviewer	American Roentgen Society	2017-
	Cancer Research UK Clinical/Translation Research Grants	2017
Advisory Board	RenovoRX	2017-
Advisory Board	Wings of Hope Pancreatic Cancer Research Foundation	2017-2019
Advisory Board	Merck	2018-2018
Advisory Board	Phillips Healthcare	2020-2021
Advisory Board	Novartis	2020-2021

Karyn A. Goodman, MD, MS

Member	Veterans Administration (VA) Rectal Cancer Blue Ribbon Panel	2021-
Member	NCI Equity Inclusion Program Subcommittee	2022-
Member	Veterans Administration (VA) Liver Tumor Blue Ribbon Panel	2022-

Extramural Leadership Positions

<i>Role</i>	<i>Name of Organization</i>	<i>Dates</i>
Co-Chair	National Cancer Institute (NCI) Gastrointestinal Steering Committee	2019- present
Co-Chair	NCTN Task Force on Diversity in GI Oncology	2020- 2025
Co-Chair	National Cancer Institute (NCI) Clinical Trials and Translational Research Advisory Committee (CTAC) Gastric and Esophageal Cancers Working Group	2021-2022

Intramural Service

<i>Activity</i>	<i>Dates</i>
<i>Icahn School of Medicine at Mount Sinai:</i> Associate Director of Clinical Research, Tisch Cancer Institute	2019 -
Fellowship Research Advisory Committee, Division of Hematology and Oncology	2020 -
Equity and Inclusion Committee, Department of Radiation Oncology	2020 -
Enterprise OnCore Governance Committee, Icahn School of Medicine at Mount Sinai	2020 –

University of Colorado:

Medical Director, Cancer Clinical Trials Office	2015-2016
Associate Director of Clinical Research, University of Colorado Cancer Center	2016-2019
Member, Department of Radiation Oncology Promotions Committee	2015-2019

MSKCC:

Disease Management Team Leader, Upper GI Malignancies	2007-2015
Institutional Review Board Member	2010-2015

Karyn A. Goodman, MD, MS

Radiation Oncology Protocol Review Committee	2007-2010
The Memorial Hospital Alumni Society, Executive Council Member	2010-2015
The Memorial Hospital Alumni Society, President	2013-2014
Colorectal Surgery Service Chief Search Committee	2011-2012
Clinical Physics Service Chief Search Committee	2011-2013
Pancreas Cancer Research Center Search Committee	2012-2013
Cancer and Fertility Advisory Group	2012-2015
Pregnancy Pre-Testing Committee	2013-2015

Stanford:

Alternate Delegate, Faculty Senate, Stanford University Medical School 2005-06

Scientific Research Council, Stanford Cancer Center 2006

RESEARCH PROFILE

As a clinician-scientist specializing in radiation oncology with a focus on the management of gastrointestinal (GI) malignancies, I have expanded the use of cutting edge technology in radiation oncology to treating GI neoplasms, including intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and stereotactic body radiotherapy (SBRT). I performed several phase I dose escalation trials of SBRT for liver tumors and pancreas cancer while at Stanford, Memorial Sloan-Kettering (MSKCC) and the University of Colorado, establishing the role of SBRT in pancreas and liver tumors. I performed multiple investigator-initiated trials evaluating the use of brachytherapy and imaging biomarkers for GI cancers. I analyzed abdominal tumor motion during therapy and developed models to predict target motion. We evaluated clinical and dosimetric factors associated with toxicity during RT and developed dose constraint recommendations to minimize the acute and long-term effects of therapy. I worked on developing appropriate guidelines and methods of quality assurance for RT in GI cancers, including national guidelines and contouring atlases that are used routinely for rectal cancer, gastric cancer, esophageal cancer and pancreas cancer. I am also involved in the development of therapeutic protocols to optimally combine systemic therapies with RT and individualize care for patients with GI cancers. I serve as the National Study Chair for Alliance/CALGB 80803 (Randomized phase II trial of PET-directed therapy for esophageal cancer) and the National Radiation Oncology Principal Investigator for the RTOG/NRG 0848 trial (Phase III trial of adjuvant chemoradiation for resected pancreas cancer). I have been involved in Health Outcomes Research, in particular, patient-reported outcomes during therapy and late effects and quality of life after treatment with RT. At Mount Sinai, I continue to study the combination of novel agents with RT for GI cancers and to incorporate the use of big data that can be extracted from the electronic medical record and molecular pathology databases to further understand predictors of response and toxicity in our patients. I serve as the Mount Sinai Principal Investigator for the NRG Oncology Cooperative group.

CLINICAL PROFILE

Karyn A. Goodman, MD, MS

I ran the GI Radiation Oncology Service for 9 years at Memorial Sloan Kettering Cancer Center (MSKCC) where I was involved in establishing the use of novel radiotherapy techniques such as IMRT and SBRT for GI cancers. I collaborated with colleagues in multiple Disease Management Teams to incorporate more targeted treatment techniques for esophageal, gastric, pancreas, rectal, and anal cancers. These new treatment approaches included brachytherapy for esophageal cancer and rectal cancer; combined chemotherapy and dose-escalated radiotherapy for pancreas, anal, and rectal cancers; and PET-based radiotherapy planning for anal and rectal cancer. I developed strategies to address respiratory motion of thoracic and abdominal tumors using respiratory gating, where we can deliver radiation only during certain times during the breathing cycle, thus minimizing radiation field sizes. I worked closely with our gastroenterologists to place fiducial markers to serve as surrogates of tumor position.

In 2015, I brought my expertise in managing GI malignancies and novel RT techniques to the University of Colorado. I introduced new approaches to the management of rectal cancer and esophageal cancer including total neoadjuvant therapy for rectal cancer and PET-directed therapy for esophageal cancer. I helped to introduce respiratory gating for patients with liver and pancreas malignancies. I developed departmental dosimetric constraints and worked with a physics resident to program a script to run site-specific constraints in the Eclipse treatment planning system. I also developed a CTCAE grading worksheet into our EPIC system to routinely grade toxicities in a discrete data element format that can be queried.

Since arriving at Mount Sinai in 2019, I have established a Pancreatic Cancer Center of Excellence and worked with my colleagues to provide a weekly Pancreas Cancer Multidisciplinary Clinic. I have also developed a more robust program to provide multidisciplinary care for patients with esophageal cancer. Overall, my goal, through my involvements in the Department of Radiation Oncology and as the Associate Director (AD) of Clinical Research in the Tisch Cancer Institute is to enhance the quality and stature of the institution and deliver the best cancer care and cutting-edge research to our patients.

IMPACT

Over the last 20 years, I have established myself as a national and international leader in GI Radiation Oncology. Through my research on the integration of cutting edge technology into the delivery of radiotherapy for GI malignancies, I have helped to establish the use of SBRT, IMRT, and IGRT in the management of GI cancers. I have developed national guidelines and contouring atlases to help radiation oncologists deliver high quality care for patients with GI malignancies. I have been an invited speaker at numerous large, national and international meetings and have been invited to be a Visiting Professor at institutions across the United States as well as internationally, including India, the United Kingdom, Germany, Portugal, Brazil, China, Canada, and Hong Kong. Through my role as the Co-chair of the NCI Gastrointestinal Steering Committee, I am directly involved with setting the strategic priorities and assessing all phase II or III trials in GI cancers that will be run through the National Clinical Trials Network. As the Associate Director of Clinical Research for the University of Colorado Cancer Center, I have built research infrastructure to support developing and conducting clinical trials, particularly investigator-initiated trials, as well as to expand access to clinical research across the UHealth System. As the AD of Clinical Research for the Tisch Cancer Institute, I serve on the TCI Executive Committee and oversee all of the cancer clinical trials at Mount Sinai. I was very involved in our competitive renewal for our NCI designation in 2025 and based on our recent site visit, we are now an NCI-Designated Comprehensive Cancer Center. In addition, Mount Sinai ranked #8 for Cancer in the United States by the U.S. News and World Reports in 2025.

GRANTS, CONTRACTS, FOUNDATION SUPPORT

ONGOING RESEARCH SUPPORT

<u>Funding Source, Project Title and Number</u>	<u>Role in Project</u>	<u>Dates</u>	<u>Direct Costs</u>	<u>Supplemental Info</u>
Title: NCI Research Specialist (Clinician Scientist) Award Project Number: R50 CA276021	PI	03/01/2023 - 02/28/2028	\$455,619 (salary support)	Major Goals: 1) To expand access to clinical trials across the Mount Sinai Health System (MSHS); 2) to increase the numbers of NCI-sponsored trials performed across the MSHS; 3) to address the need for more oversight and integration of clinical trial services provided across the MSHS; 4) to support junior faculty to develop investigator-initiated trials (IITs) and present concepts to the Experimental Therapeutic Clinical Trials Network (ETCTN) for potential support; and, 5) to increase minority recruitment to TCI clinical trials.
Lustgarten Foundation Equity, Accessibility and Diversity (LEAD) Project Grant	Overall PI	11/01/2023 - 10/30/2028	\$450,000	Multi-site Project with Johns Hopkins and Northwell Health Goal: To provide navigated pancreatic cancer multidisciplinary care to address cultural and language barriers to clinical trial enrollment among Mandarin and Spanish-speaking patients with pancreatic cancer
The Tisch Cancer Institute – Cancer Center Support Grant Project number: P30 CA196521 (PI: Parsons, R)	AD of Clinical Research	8/01/2015 – 07/31/2025	\$1,556,601	The mission of the Tisch Cancer Institute is to advance basic, clinical and population health cancer research, so as to prevent cancer in healthy individuals and improve the lives of cancer patients and their

				families in our diverse communities.
The Cancer Canopy Collective Pancreas Cancer Learning Network	PI	12/23/2021 - 12/22/2025	\$500,000	The goal of the Canopy Cancer Collective is to create a comprehensive pancreas cancer learning network in which they can provide multidisciplinary, innovative, evidence based compassionate care for ALL pancreas cancer patients throughout their entire cancer trajectory.
P30 Cancer Center Administrative Supplement: NCI Early Drug Development Opportunity Program (EDDOP) Project number: 3 P30 CA196521-06S1	PI	8/13/20 – 08/12/23	\$50,000 per year	This funding supports the cost of opening Experimental Therapeutics Clinical Trials Network (ETCTN) trials at Mount Sinai.

PAST GRANTS

<u>Funding Source, Project Title and Number</u>	<u>Role in Project</u>	<u>Dates</u>	<u>Direct Costs</u>	<u>Supplemental Info</u>
Southwest Early Clinical Trials Consortium Experimental Therapeutics Clinical Trials Network (ETCTN) /NCI UM1 Grant Project number: 1UM1CA186688	Co-I	03/14/2014 to 01/31/2020		The overall goal of this project is to participate as a site (with MD Anderson) in the NCI Experimental Therapeutics Clinical Trials Network for the development of novel agents.
P30 Cancer Center Administrative Supplement for Tobacco Use Treatment in Cancer Patients Project number: 3P30CA046934 29S2	Co-I	09/01/17 – 08/30/21		This funding supports the development of a comprehensive smoking cessation program in the University of Colorado Cancer Center.
Cancer League of Colorado Investigator Initiated Trial Grant Project Number: COMIRB # 16-1139	PI	12/16 – 12/19	\$50,000	This funding supported the correlative science studies embedded in a dose-escalation trial of 3 fraction SBRT for pancreatic cancer
Biomarker, Imaging, and Quality of Life Studies Funding Program (BIQSFP) Sub-contract number: 11XS249 CALGB 80803: Randomized Phase II Study of PET Scan-	Co-PI, CALGB 80803 Study Chair	4/30/12 - 6/30/16	\$626,608	Obtained Biomarker, Imaging, and Quality of Life Studies Funding Program (BIQSFP) funding to cover the cost of PET scans which

Directed Combined Modality Therapy in Esophageal Cancer				were an integral biomarker
The Imaging and Radiation Sciences Program (IMRAS) Project Number: MSKCC IRB #15-109	PI	10/14-9/15	\$200,000	Novel predictive imaging biomarkers of tumor response and gastrointestinal toxicity during and after stereotactic body radiotherapy for locally advanced pancreatic cancer using diffusion-weighted and dynamic contrast enhanced MRI.
David Rubenstein Center for Pancreatic Research Pilot Fund Project Number: MSKCC IRB #15-109	PI	01/15-1/16	\$100,000	Evaluation of predictive molecular biomarkers of tumor response after stereotactic body radiotherapy for locally advanced pancreatic cancer using MSKCC IMPACT assay.
American Society of Clinical Oncology (ASCO) Young Investigator Award Long-Term Outcomes of Survivors of Autologous Hematopoietic-Cell Transplantation for Refractory and Relapsed Hodgkin's Disease	PI	09/07/04-12/31/05	\$35,000	
Lerner Family Foundation Development and Evaluation of Novel EGFR PET Probes to More Effectively Eradicate Esophageal and Other EGFR-positive Cancers	Co-PI	2005-2007	\$150,000	
Varian Medical Systems Phase II to Evaluate Chemoradiotherapy for Pancreatic Cancer	Co-I	01/01/05-12/31/06	\$100,000	
Stanford University Dean's Fellowship Award The Development of PET based in-Vivo Imaging of Epidermal Growth Factor Receptor Expression in Esophageal Tumor Models	Co-I	2006-07	\$20,000	
Lacher Lymphoma Foundation Fellowship Long-Term Outcomes of Survivors of Autologous Hematopoietic-Cell Transplantation for Refractory and Relapsed Hodgkin's Disease.	Co-I	7/02-6/03	\$10,000	

CLINICAL TRIALS PARTICIPATION

Karyn A. Goodman, MD, MS

Leadership in National Clinical Trials Network (NCTN) and Experimental Therapeutics Clinical Trials Network (ETCTN) Protocols:

CALGB 80803: Randomized phase II trial of PET-directed therapy for esophageal cancer
Role: National Study Chair

RTOG/NRG 0848: Phase III trial of adjuvant chemoradiation for resected pancreas cancer
Role: National Radiation Oncology Principal Investigator

ETCTN 10366: Phase 1/2 trial of M3814 (Peposertib) in combination with SBRT in patients with localized pancreatic adenocarcinoma
Role: Co-Principal Investigator, Radiation Oncology PI, Mentor for early career faculty (Dr. Lindsay Davis) for M3814 Team Science Award

Institutional IRB-Approved Protocols:

Mount Sinai

Project	Role in Project	Dates
Evaluating the impact of chemotherapy and pelvic radiotherapy on the gut microbiome: a potential predictive biomarker for GI toxicities and clinical outcomes in patients with rectal and anal cancer	PI	9/6/24 - Present
An Investigation of the Role of Germ-Line Mutations in Cancer Predisposition, Tumor Biology an Response to Treatment – Collaboration with UCLA	PI	3/3/25 – Present
A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)	PI	7/16/2024 - Present
Validation of the CytoRADx™ System with Human Subjects Receiving Localized Radiation Therapy	PI	10/3/2023 - 5/2/2025
ETCTN 10366: A multicenter study with an open-label Phase Ib part followed by a randomized, placebo-controlled, double-blind, Phase II part to evaluate efficacy, safety, tolerability, and pharmacokinetics of the DNA-protein kinase (DNA-PK) inhibitor M3814 in combination with capecitabine and radiotherapy in participants with locally advanced rectal cancer	PI	12/1/2020 – present
EA2182: Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)	PI	11/1/20-12/31/2024

EA2174: A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma	PI	01/17/19-8/1/2024
SKYSCRAPER 07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab With Or Without Tiragolumab (Anti-Tigit Antibody) In Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma	PI	04/02/21 - 05/20/23

University of Colorado

Project	Role in Project	Dates
# 18-2684 Understanding Barriers to Enrollment in Clinical Trials at University Colorado Cancer Center	PI	2/16/19 – 9/14/19
# 18-1216 A Randomized Phase II Study of Nivolumab after Combined Modality Therapy (CMT) in High Risk Anal Cancer (EA2165)	PI	11/26/18- 9/14/19
# 16-2424 Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer (NRG GI002)	PI	4/11/17-9/14/19
# 16-1139: A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) after Induction Chemotherapy for Locally Advanced Pancreatic Cancer	PI	9/15/16-9/14/19
# 16-0082: A phase II multicenter randomized trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or non-operative management	PI	9/1/16-9/14/19
# 15-2307 A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (RTOG 0848)	PI	6/15/16-9/14/19

MSKCC

Project	Role in Project	Dates
# 14-104: A Phase I, Dose Escalation Trial of Endoluminal High Dose Rate Brachytherapy with	PI	6/18/14-9/1/15

Concurrent Chemotherapy for Rectal or Anal Cancer in Patients with Recurrent Disease or Undergoing Non-Operative Management		
#13-250: Randomized Phase III Study OF Sorafenib versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma (RTOG 1112)	PI	4/9/14-9/1/15
#13-213: A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients with Locally Advanced Rectal Cancer Treated with Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management	PI	11/26/2013-9/1/15
#13-019 Pilot Study of Advanced MR Imaging for Early Biologic Tumor Changes to Neoadjuvant Chemoradiation Treatment for Rectal Cancer	PI	04/09/2013-9/1/15
#12-087, PROSPECT Trial: A phase II/III trial of neoadjuvant FOLFOX, with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision (NCCTG N1048)	Co-PI	5/15/12-9/1/15
#12-011, Phase II trial of PET scan-directed combined modality therapy in esophageal cancer (CALGB 80803)	Co-PI	1/24/12-9/1/15
#10-178, Phase II Multi-institutional Study to Evaluate Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma.	PI	11/23/10-9/1/15
#10-083, A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (RTOG 0848)	PI	6/22/10-9/1/15
#10-014, A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed by Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC) (SWOG 0809)	PI	2/23/2010-10/09/12 (closed to accrual date)
#09-066, A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Who Are Treated Without Surgery (RTOG 0436)	PI	9/22/09-8/09/11 (closed to accrual date)
#08-127, A Descriptive Study of Vaginal Dilator Use after Pelvic Radiotherapy	Co-PI	11/11/08-9/1/15
#94-045, Phase III Evaluation of 5-FU by Bolus vs. 5-FU by Prolonged IV Before & After Combined IV & Pelvic XRT vs. Bolus 5 FU & Leucovorin & Levamisole Before and After Combined Pelvis XRT & Bolus 5-FU	PI	5/10/94-11/10/09

& Leocovorin in Patients with Rectal Cancer (INTERGP S9304) (RTOG 9403)		
#07-151, A Feasibility Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Colorectal Cancer Patients Dates:	Co-PI	12/11/07-9/1/17
#07-021, A Pilot Study of Neoadjuvant Chemotherapy with Selective Use of Radiation for Locally Advanced Rectal Cancer	Co-PI	3/20/07-1/26/10 (closed to accrual date)
#06-055, Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma (CALGB 80101)	Co-PI	6/13/06-10/28/08 (close to accrual date)
#02-061, A Phase I Trial of Irinotecan, Radiation Therapy, and Escalating Doses of Docetaxel With or Without Cisplatin in Locally Advanced Esophageal Cancer	Co-PI	4/4/03-12/22/09
#02-057, A Phase I Study of Alvocidib (Flavopiridol) in Combination With Radiation in Locally Advanced, Non-Operable Pancreatic Cancer and Extrahepatic Bile Duct Cancers (NCI #5764)	Co-PI	8/16/02-8/26/08
#12-094, A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma, PI Abraham Wu, M.D. was recently approved by the IRB (RTOG 1010)	Investigator	6/15/12 – 9/1/15
#09-088, A Phase II Trial of Pre-operative Irinotecan, Cisplatin and Radiation in Esophageal Cancer (CALGB 80302)	Investigator	10/13/09-7/26/11 (closed to accrual date)
#08-073, The Sexual Health of Rectal Cancer Patients: A Pilot Study	Investigator	6/24/08-9/1/15
#06-151, Functional Outcomes and Quality of Life in Patients Undergoing Surgery for Rectal Cancer Dates:	Investigator	11/28/06-11/24/09
#03-020, Long-Term Outcomes of Survivors of Autologous Hematopoietic-Cell Transplantation for Refractory and Relapsed Hodgkin's Disease	Co-PI	2/25/03-5/24/05

Stanford, PI:

Project	Role in Project	Dates
#95523, Long-Term Outcomes of Survivors of Autologous Hematopoietic-Cell Transplantation for Refractory and Relapsed Hodgkin's Disease ASCO Young Investigator Award	PI	10/4-12/06
#79517, Dose Escalation Study Evaluating Stereotactic Radiosurgery for Liver Malignancies	PI	10/04-12/06

Karyn A. Goodman, MD, MS

#96405, Quality of life and Functional Outcomes after Combined Modality Therapy for Anal Cancer: A Comparison of Conventional versus Intensity-Modulated Radiation Therapy	PI	9/05-12/06
#79517, Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer	PI	10/05-12/06
#96075, Phase I Study of Dose Escalation Using Image-guided Radiotherapy to Deliver a Stereotactic Radiosurgical Boost after Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Esophageal Cancer	PI	6/06-12/06

Grant Review Activities

2014- 2015	American Association of Cancer Research/ SU2C-Farrar Fawcett Foundation Joint Scientific Advisory Committee
2018 – Present	Cancer Research UK
2015 – Present	Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – MRI Linear Accelerator Research Project Study Section

TRAINEES

<u>Name</u>	<u>Level of Trainee</u>	<u>Role in Training</u>	<u>Training Venue</u>	<u>Current Status/Employment/ Achievements</u>
Daniel Cherry, Icahn School of Medicine at Mount Sinai	Resident	<ul style="list-style-type: none"> • Research advising • Career advising 	Clinical Research	Oral presentations on research projects at ARS and ASTRO
Daniel Dickstein, Icahn School of Medicine at Mount Sinai	Resident	<ul style="list-style-type: none"> • Research advising • Career advising • Advisor for ASCO Young Investigator Award 	Clinical Research	Assistant Professor, Icahn School of Medicine at Mount Sinai on Aug. 1, 2025 Peer reviewed publications: PMID: 40057858 PMID: 38763974
Alexandra Hotca-Cho, Icahn School of Medicine at Mount Sinai	Resident	<ul style="list-style-type: none"> • Research advising • Career advising • Co-author on Chapter, editorial • Co-investigator on 2 clinical trials 	Clinical Research	Assistant Professor at UCSF Peer reviewed publications: PMID: 36634301 PMID: 35561302
Brianna Jones, Icahn School of Medicine at Mount Sinai	Resident	<ul style="list-style-type: none"> • Research advising • Career advising • Co-author on Chapter 	Clinical Research	Assistant Professor at Northwell-Hofstra School of Medicine Peer reviewed publications: PMID: 36590376 PMID: 36395802
Julie Bloom, Icahn School of Medicine at Mount Sinai	Resident	<ul style="list-style-type: none"> • Research advising • Career advising • Co-investigator on clinical trial 	Clinical Research	Assistant Professor, Icahn School of Medicine at Mount Sinai Mentored development of an

Karyn A. Goodman, MD, MS

				IRB approved protocol on vaginal dilator and pelvic floor physical therapy for women undergoing pelvic RT Peer reviewed publications: PMID: 38550368
Anthony Nehlsen, Icahn School of Medicine at Mount Sinai	Resident	<ul style="list-style-type: none"> • Research advising • Career advising • Co-author on Chapter 	Clinical Research	Assistant Professor, Icahn School of Medicine at Mount Sinai Peer reviewed publications: PMID: 33831248 PMID: 36590376
Arya Amini, University of Colorado	Resident	<ul style="list-style-type: none"> • Research advising • Career advising • Co-author on Chapter 	Clinical Research	Assistant Professor, City of Hope Cancer Center Peer reviewed publication in <i>Cancer</i> . PMID: 27571233 2 chapters in: <i>Theodore Hong and Prajnan Das (Eds): Radiation Therapy for Gastrointestinal Cancers</i>
Matthew Jackson, University of Colorado	Resident	<ul style="list-style-type: none"> • Research advising 	Clinical Research	Radiation Oncologist, Santa Fe, NM Peer reviewed publication in <i>Cancer Journal</i> . PMID: 27441741
Priscilla Stumpf, University of Colorado	Resident	<ul style="list-style-type: none"> • Research advising • Developing prospective quality improvement project for Rad Onc Palliative Care • Co-author on Review Article 	Clinical Research	Assistant Professor, University of Colorado Peer reviewed publications: PMID: 33864824 PMID: 28513823
Supriya Jain, University of Colorado	Resident	<ul style="list-style-type: none"> • Research advising • Developing prospective trial • Co-author on Chapter 	Clinical Research	Radiation Oncologist, Fort Collins, CO 2 chapters in: <i>Jyoti Mayadev et al. (Eds): Handbook of Image-Guided Brachytherapy</i>
Jean Wright, MSKCC	Resident	<ul style="list-style-type: none"> • Research advising • Career advising 	Clinical Research	Chair of Radiation Oncology, UNC 3 peer reviewed publications. PMID: 23692961 PMID: 21825888 PMID: 20350793
Stephanie Terezakis, MSKCC	Resident	<ul style="list-style-type: none"> • Research advising • Career advising 	Clinical Research	Chair of Radiation Oncology, University of Minnesota 1 peer reviewed publication. PMID: 25631062
Anuj Goenka, MSKCC	Resident	<ul style="list-style-type: none"> • Research advising • Career advising 	Clinical Research	Associate Professor, Northwell Health, Hofstra Medical School Completed masters in epidemiology program at Columbia University under my mentorship

Karyn A. Goodman, MD, MS

Marsha Reyngold, MSKCC	Resident	<ul style="list-style-type: none"> • Research advising • Career advising 	Clinical Research	Associate Professor, MSKCC 3 peer-reviewed publications PMID: 24586085 PMID: 29556578 PMID: 28661823
Sarah Milgrom, MSKCC	Resident	<ul style="list-style-type: none"> • Research advising • Co-author on Chapter • Development of clinical trial • Career advising 	Clinical Research	Assistant Professor, University of Colorado 3 peer reviewed publications PMID: 24052311 PMID: 24604589 PMID: 25323613 One review article PMID: 22488095
Michael Folkert, MSKCC	Resident	<ul style="list-style-type: none"> • Research advising • Co-author on chapter • Development of clinical trial • Career advising 	Clinical Research	Associate Professor, Northwell Health, Hofstra Medical School 1 peer-reviewed Publication PMID: 23434221 Chapter in: N. Lee, J.J. Lu (eds.), <i>Target Volume Delineation and Field Setup</i>
Jonathan Yang, MSKCC	Resident	<ul style="list-style-type: none"> • Research advising • Co-author on Review article • Career advising 	Clinical Research	Associate Professor, NYU 4 peer-reviewed publications PMID: 27751605 PMID: 25936810 PMID: 25304718 PMID: 24312686 One review article PMID: 25830042
Carla Hajj, MSKCC	Resident	<ul style="list-style-type: none"> • Research advising • Development of clinical trial • Co-author on Chapter • Career advising 	Clinical Research	Assistant Professor, MSKCC 4 peer-reviewed publications PMID: 23077685 PMID: 24717570 PMID: 27751605 PMID: 27796165 4 review articles PMID: 25918298 PMID: 26549996 PMID: 22532174 PMID: 23936549
Tina DasGupta, UCSF	Resident	<ul style="list-style-type: none"> • Research advising • Co-author on Chapter • Career advising 	Clinical Research	Radiation Oncologist, Atlanta, GA 1 peer-reviewed publication PMID: 23692961 Chapter in: <i>Radiation Medicine Rounds: Lower GI Malignancies</i> . Eds. Ben-Josef E, Koong A
Arpit Chhabra, SUNY Downstate	Resident	<ul style="list-style-type: none"> • Research advising • Career advising 	Clinical Research	Assistant Professor, Icahn School of Medicine at Mount Sinai 1 peer-reviewed publication PMID: 26657654
Gayle Tillman, Stanford Medical Center	Resident	<ul style="list-style-type: none"> • Research advising • Development of clinical trial • Career advising 	Clinical Research	Clinical Faculty, Massachusetts General Hospital 1 peer-reviewed publication PMID: 19125798

Karyn A. Goodman, MD, MS

Ellen Wiegner, Stanford Medical Center	Resident	<ul style="list-style-type: none"> • Research advising • Career advising 	Clinical Research	Radiation Oncologist, Sacramento, CA 1 peer-reviewed publication PMID: 20350791
Yuri Minn, Stanford Medical Center	Resident	<ul style="list-style-type: none"> • Research advising • Development of clinical research • Career advising 	Clinical Research	Radiation Oncologist, San Francisco, CA 5 peer-reviewed publication PMID: 22966754 PMID: 20564136 PMID: 20056345 PMID: 19732129 PMID: 19398901 Radiation Oncologist at Kaiser Permanente
Shu Ng, Monash University Medical School	Resident	<ul style="list-style-type: none"> • Research advising • Career advising 	Clinical Research	2 peer-reviewed publications PMID: 27152887 PMID: 27751605
Douglas Rooke, University of Colorado	Medical Student	<ul style="list-style-type: none"> • Mentor for UCAnschutz Medical Student Research 	Clinical Research	Resident at OHSU
Noah Kastelowitz- Lieberman, University of Colorado	Medical Student	<ul style="list-style-type: none"> • Mentor for UCAnschutz Medical Student Research 	Clinical Research	Instructor in Radiation Oncology at Stanford
Jason Kwah, Drexel School of Medicine	Medical Student	<ul style="list-style-type: none"> • Mentor for Summer Medical Student Research 	Clinical Research	Internist in PA One peer-reviewed publication PMID: 22284687
Osa Aghayere, University of Rochester School of Medicine	Medical Student	<ul style="list-style-type: none"> • Mentor for Summer Medical Student Research • Career advising 	Clinical Research	PMID: 22284687
Mindy Griffith, University Buffalo School of Medicine	Medical Student	<ul style="list-style-type: none"> • Mentor for Summer Medical Student Research 	Clinical Research	One peer-reviewed publication PMID: 23077685
Libertad Flores, Brown University School of Medicine	Medical Student	<ul style="list-style-type: none"> • Mentor for Summer Medical Student Research • Career advising 	Clinical Research	OB/GYN in Rhode Island One peer-reviewed publication PMID: 23077685 Completed Ob/Gyn Residency
Thomas Kole, University of Medicine and Dentistry of New Jersey	Medical Student	<ul style="list-style-type: none"> • Mentor for Medical Student Research • Career advising 	Clinical Research	Clinical Assistant Professor of Medicine, The Icahn School of Medicine, Mount Sinai, Valley Health System 1 peer-reviewed publication PMID: 22284687
Shreya Prasad, Duke University	Medical Student	<ul style="list-style-type: none"> • Mentor for Medical Student Research 	Clinical Research	Medical Oncology Fellow at Northwell Health 1 peer-reviewed publication PMID: 26577010
Diana Rothenstein Julie, State	Medical Student	<ul style="list-style-type: none"> • Mentor for Medical Student Research 	Clinical Research	Radiation Oncology Resident at Cornell University 2 peer-reviewed publication

Karyn A. Goodman, MD, MS

University of New York, Downstate				PMID: 23692961 PMID: 25984929 1 review article PMID: 26905274
Margaret Davidson, Johns Hopkins University	Undergrad	<ul style="list-style-type: none"> Mentor for Undergraduate Student Research 	Clinical Research	Went to Peace Corp
Ashlyn Tom, New York University	Undergrad	<ul style="list-style-type: none"> Mentor for Undergraduate Student Research Career advising 	Clinical Research	PhD Candidate in Implementation Science at University of Washington, MPH program at Johns Hopkins 3 peer-reviewed publications PMID: 26164775 PMID: 25984929 PMID: 28884454

TEACHING ACTIVITIES

<u>Teaching Activity/Topic</u>	<u>Level</u>	<u>Role</u>	<u>Number of Learners</u>	<u>Number of hours</u>	<u>Evaluation Summary</u>	<u>Years Taught</u>
Stanford University School of Medicine Radiation Oncology Medical Student Clerkship Director	Medical School Course	Director	5-10 per year	10 hrs/week	Outstanding evaluation for rotation	2004-2006
MSKCC Radiation Oncology Department Resident Education Committee	Department	Member	20 per year	1-2 hrs/week		2010-2015
Annual GI Radiation Oncology One-Month Teaching Block at Stanford, MSKCC and University of Colorado	Department	Lecturer	10-20 per year	2-3 hrs/week for one month per year		2004-2019
Weekly one-on-one didactic teaching session with Residents	Department	Lecturer	4 per year	1 hr per week	Outstanding teaching evaluations	2004-present
Surgical Oncology Fellowship Block in Radiation Oncology at MSKCC	Institution	Director	3-4 per year	5-6 hrs per week, 3-4 weeks per year		2010-2015
MSKCC Resident GI Radiation Oncology Rotation	Department	Teaching/Attending	4 per year	10 hrs per week	Outstanding teaching evaluations	2010-2015
ASCO/AACR Methods in Clinical Cancer Research Workshop at Vail	National	Lecturer/Teacher	100 per year	40 hrs over one week	Won mentorship award in 2019	2016-present
University of Colorado Resident GI Radiation Oncology Rotation	Department	Teaching/Attending	4 per year	10 hrs per week	Outstanding teaching evaluations	2015-2019

Karyn A. Goodman, MD, MS

Mount Sinai Resident GI Radiation Oncology Rotation	Department	Teaching/ Attending	4 per year	10 hrs per week	Outstanding teaching evaluations	2019-present
---	------------	------------------------	------------	--------------------	--	--------------

ADMINISTRATIVE LEADERSHIP APPOINTMENTS

INTERNAL:

<u>Organization</u>	<u>Role</u>	<u>Impact</u>	<u>Dates</u>
Stanford University School of Medicine	Radiation Oncology Medical Student Clerkship Director	Setting strategic priorities for the National Clinical Trials Network GI studies in the U.S.	2004-2006
Memorial Sloan Kettering Cancer Center	Director of GI Radiation Oncology	Established use of novel RT techniques for GI cancers	2007-2015
Memorial Sloan Kettering Cancer Center	Upper GI Disease Team Co-Leader	Established research and clinical priorities for Upper GI Cancers, submitted P30 Grant supporting documentation for Upper GI Cancer research	2007-2015
Memorial Hospital Alumni Society	President	Organized the Annual Alumni Society Conference	2014-2015
University of Colorado Cancer Center	Medical Director, Cancer Clinical Trials Office	Oversaw 150 clinical research staff, managed budget for an \$11 million operation. Re-organized and streamlined administrative processes	2015-2016
University of Colorado Cancer Center	Associate Director of Clinical Research	Implemented new processes, programs, and infrastructure to support the growth of investigator-initiated trials and expand clinical trials across the UHealth system	2016-2019
Icahn School of Medicine at Mount Sinai	Associate Director of Clinical Research	Implemented new processes, programs, and infrastructure to support the growth of investigator-initiated trials and expand clinical trials across the Mount Sinai Health System	2019-present

EXTERNAL

Karyn A. Goodman, MD, MS

National Leadership Roles:

<i>Organization</i>	<i>Role</i>	<i>Impact</i>	<i>Dates</i>
National Cancer Institute (NCI) Clinical Trials and Translational Advisory Committee (CTAC)	Member	CTAC provides broad scientific and programmatic advice on the investment of taxpayer dollars in clinical trials and translational research across NCI.	7/2025 -
Veteran's Health Administration (VHA) Blue Ribbon Panel for Rectal Cancer and Liver Cancer	Member	Set the quality measures for radiation therapy for patients with rectal and liver cancers at the VA.	6/2022 -
National Cancer Institute (NCI) Equity Council EIP Subcommittee	Member	Evaluate equity and inclusion for the NCTN groups	1/2022 -
National Clinical Trial Network (NCTN) Task Force on Diversity in GI Oncology	Co-Chair	Establish guidelines to improve equity and inclusion in NCTN groups	1/2021 -
American College of Radiation Oncology(ACRO)/Radiosurgery Society(RSS) Accreditation Committee for Liver Cancers	Chair	Establish the quality measures for stereotactic body radiotherapy for liver cancers.	2/2020 -
National Cancer Institute (NCI) Gastrointestinal Steering Committee	Co-Chair	Setting strategic priorities for the National Clinical Trials Network GI studies in the U.S.	1/2019 -
National Comprehensive Cancer Network (NCCN) Board of Directors	Member	Establishing overall vision for NCCN	1/2019-9/2019
American Association of Cancer Research (AACR)/American Society of Clinical Oncology (ASCO) Vail Methods in Clinical Cancer Research Workshop	Faculty Member	Training the next generation of clinical trialists in the U.S.	7/2016-2023
Cancer and Leukemia Group B (CALGB)/Alliance for Clinical Trials in Oncology GI Committee	Cadre Member and National Study Chair of CALGB 80803	Developed and led the CALGB 80803 Trial, A Phase II trial of PET scan-directed combined modality therapy in esophageal cancer	3/2009-
Radiation Therapy Oncology Group (RTOG)/NRG GI Committee	Cadre Member and National Radiation Oncology Co-PI of RTOG 0848	Developed and led the RTOG 0848 Trial, A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma	1/2007-
American Society of Therapeutic Radiation and Oncology (ASTRO) Rectal Cancer Best Practices Working Group	Committee Chair	Developed national guidelines/best practices for locally advanced rectal cancer	2012-2017

Karyn A. Goodman, MD, MS

American Society of Clinical Oncology (ASCO) Gastrointestinal Symposium	Co-Chair	Organized and set priorities for the GI ASCO Symposium	2016-2017
American Society of Clinical Oncology (ASCO) Gastrointestinal Symposium	Chair	Organized and set priorities for the GI ASCO Symposium	2017-2018

BIBLIOGRAPHY

Peer Reviewed Original Contributions

1. Spitz AM, Velebil P, Koonin LM, Strauss LT, **Goodman KA**, Wingo P, Wilson JB, Morris L, Marks JS. Pregnancy, Abortion, and Birth Rates Among U.S. Adolescents—1980, 1985, 1990. *JAMA*. 1996; 275(13):989-94.
2. **Goodman KA**, Birdwell RL, Ikeda DM. Compliance with Recommended Follow-up After Percutaneous Core Breast Biopsy. *AJR Am J Roentgenol*. 1998; 170:89-92.
3. **Goodman KA**, Ballagh SA, Carpio A. Case-control Study of Seropositivity for Cysticercosis in Cuenca, Ecuador. *Am J Trop Med Hyg*. 1999; 60(1): 70-74.
4. **Goodman KA**, Sneed PK, McDermott MW, Shiau CY, Lamborn KR, Chang WM, Larson DA. Relationship Between Pattern of Enhancement and Local Control of Brain Metastases After Radiosurgery. *Int J Radiat Oncol Biol Phys*. 2001; 50(1):139-46.
5. **Goodman KA**, Wolden SL, La Quaglia MP, Kushner BH. Whole Abdominopelvic Radiation Therapy for Desmoplastic Small Round-Cell Tumors. *Int J Radiat Oncol Biol Phys*. 2002; 54(1):170-176.
6. **Goodman KA**, Wolden SL, La Quaglia MP, Alektiar K, D'Souza D, Zelefsky MJ. Intraoperative High-Dose Rate Brachytherapy for Pediatric Solid Tumors: A 10-year Experience. *Brachytherapy* 2003; 2(3):139-146.
7. **Goodman KA**, Hong L, Wagman R, Hunt M, McCormick BA. Dosimetric Analysis of a Simplified Intensity Modulation Technique for Prone Breast Irradiation. *Int J Radiat Oncol Biol Phys*. 2004; 60(1):95-102.
8. **Goodman KA**, Toner S, Hunt M, Wu EJ, Yahalom J. Intensity Modulated Radiation Therapy in the Treatment of Lymphoma Involving the Mediastinum. *Int J Radiat Oncol Biol Phys*. 2005; 61(1): 198-206.
9. Koong AC, Christofferson E, Le QT, **Goodman KA**, Ho A, Kuo T, Ford JM, Fisher GA, Greco R, Norton J, Yang GP. Phase II Study to Assess the Efficacy of Conventionally Fractionated Radiotherapy Followed by a Stereotactic Radiosurgery Boost in Patients with Locally Advanced Pancreatic Cancer. *Int J Radiat Oncol Biol Phys*. 2005; 63(2):320-3.
10. Li T, Schreibmann E, Thorndyke B, Tillman G, Boyer A, Koong A., **Goodman K**, and Xing L: Dose Reduction in Four-Dimensional Computed Tomography. *Medical Physics* 2005; 32(12): 3650-3660.
11. Patel DA, Chang ST, **Goodman KA**, Quon A, Thorndyke B, Gambhir SS, McMillan A, Loo BW Jr, Koong AC. Impact of integrated PET/CT on variability of target volume delineation in rectal cancer. *Technol Cancer Res Treat*. 2007; 6(1):31-6.
12. Chang ST, **Goodman KA**, Yang GP, Koong AC. Stereotactic body radiotherapy for unresectable pancreatic cancer. *Front Radiat Ther Oncol*. 2007; 40:386-94.

13. Roohipour R, Patil S, **Goodman KA**, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK. Squamous-cell Carcinoma of the Anal Canal: Predictors of Treatment Outcome. *Dis Colon Rectum*. 2008; 51(2):147-53.
14. Cupp JS, Koong AC, Fisher GA, Norton JA, **Goodman KA**. Tissue Effects after Stereotactic Body Radiotherapy using Cyberknife for Patients with Abdominal Malignancies. *Clin Oncol (R Coll Radiol)*. 2008; 20(1):69-75.
15. Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, **Goodman KA**, Minsky BD, Wong WD, Weiser MR. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. *Cancer*. 2008; 113(1):57-64.
16. Tillman GF, Pawlicki T, Koong AC, **Goodman KA**. Preoperative versus postoperative radiotherapy for locally advanced gastroesophageal junction and proximal gastric cancers: a comparison of normal tissue radiation doses. *Dis Esophagus*. 2008; 21(5):437-444.
17. Schellenberg D, **Goodman KA**, Lee F, Chang S, Kuo T, Ford JM, fisher GA, Quon A, Desser TS, Norton J, Greco R, Yang GP, Koong AC. Gemcitabine Chemotherapy and Single-Fraction Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer. *Int J Radiat Oncol Biol Phys*. 2008; 72(3):678-86.
18. **Goodman KA**, Riedel E, Serrano V, Gulati S, Moskowitz CH, Yahalom J. Long-Term Effects of High-Dose Chemotherapy and Radiation for Relapsed and Refractory Hodgkin Lymphoma. *J Clin Oncol*. 2008; 26(32):5240-7.
19. Chang DT, Schellenberg D, Shen J, Kim J, **Goodman KA**, Fisher GA, Ford JM, Desser T, Quon A, Koong AC. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. *Cancer*. 2009; 115(3):665-72.
20. Ku GY, **Goodman KA**, Rusch VW, Ilson DH. Successful treatment of esophageal cancer with airway invasion with induction chemotherapy and concurrent chemoradiotherapy. *J Thorac Oncol*. 2009; 4(3):432-4.
21. Weiser MR, Quah HM, Shia J, Guillem JG, Paty PB, Temple LK, **Goodman KA**, Minsky BD, Wong WD. Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. *Ann Surg*. 2009; 249(2):236-42.
22. Lee IH, Hayman JA, Landrum MB, Tepper J, Tao ML, **Goodman KA**, Keating NL. Treatment recommendations for locally advanced, non-small cell lung cancer: The influence of physician and patient factors. *Int J Radiat Oncol Biol Phys*. 2009; 74(5):1376-84.
23. Minn AY, Schellenberg D, Maxim P, Suh y, McKenna S, Cox B, Dieterich S, Xing L, Graves E, **Goodman KA**, Chang D, Koong AC. Pancreatic Tumor Motion on a Single Planning 4D-CT Does Not Correlate With Intrafraction Tumor Motion During Treatment. *Am J Clin Oncol*. 2009; 32(4):364-8.

24. Santoro JP, Yorke ED, **Goodman KA**, Mageras GS. From phase-based to displacement gating: A software tool to facilitate respiration-gated radiation treatment. *J Appl Clin Med Phys*. 2009; 10(4):132-141.
25. Rizk NP, Tang L, Adusumilli PS, Bains MS, Akhurst TJ, Ilson D, **Goodman K**, Rusch VW. Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. *J Thorac Oncol*. 2009 Jul; 4(7):875-9.
26. La TH, Minn AY, Su Z, Fisher GA, Ford JM, Kunz P, **Goodman KA**, Koong AC, Chang DT. Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. *Dis Esophagus*. 2010 May; 23(4):300-8.
27. Schellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, Fisher GA, **Goodman KA**, Koong AC, Chang DT. (18)Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy. *Int J Radiat Oncol Biol Phys*. 2010 Aug 1; 77(5):1420-5.
28. **Goodman KA**, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, Gibbs YC, Fisher GA, Koong AC. Dose Escalation Study of Single Fraction Stereotactic Body Radiotherapy for Liver Malignancies. *Int J Radiat Oncol Biol Phys*. 2010 Oct 1; 78(2):486-93.
29. Wright JL, Patil SM, Temple LF, Minsky BD, Saltz LB, **Goodman KA**. Squamous Cell Carcinoma of the Anal Canal: Patterns and Predictors of Failure and Implications for Intensity-Modulated Radiation-Treatment Planning. *Int J Radiat Oncol Biol Phys*. 2010 Nov 15; 78(4):1064-72.
30. Fuller CD, Nijkamp J, Duppen JC, Rasch CR, Thomas CR Jr, Wang SJ, Okunieff P, Jones WE 3rd, Baseman D, Patel S, Demandante CG, Harris AM, Smith BD, Katz AW, McGann C, Harper JL, Chang DT, Smalley S, Marshall DT, **Goodman KA**, Papanikolaou N, Kachnic LA; on behalf of the Radiation Oncology Committee of the Southwest Oncology Group. Prospective Randomized Double-Blind Pilot Study of Site-Specific Consensus Atlas Implementation for Rectal Cancer Target Volume Delineation in the Cooperative Group Setting. *Int J Radiat Oncol Biol Phys*. 2011 Feb 1; 79(2):481-9.
31. Minn AY, Hsu A, La TH, Kunz PL, Fisher GA, Ford JM, Norton JA, Visser B, **Goodman KA**, Koong AC, Chang DT. Comparison of IMRT and 3D Conformal Radiotherapy for Adjuvant Therapy for Gastric Cancer. *Cancer*. 2010 Aug 15;116(16):3943-52
32. DiMaio C, **Goodman KA**, Ho A, Nagula S, Schattner M, Markowitz A, Gerdes H. EUS-Guided Fiducial Placement for Image-Guided Radiation Therapy in Gastrointestinal Malignancies Using a 22-gauge Needle. *Gastrointest Endosc*. 2010 Jun; 71(7):1204-10.
33. Zhang Q, Hu YC, Liu F, **Goodman K**, Rosenzweig KE, Mageras GS. Correction of motion artifacts in cone-beam CT using a patient-specific respiratory motion model. *Med Phys*. 2010 Jun; 37 (6): 2901-9.
34. Vijayaraghavan A, Efrusy MB, **Goodman KA**, Santas CC, Huh WK. Cost-effectiveness of Human Papillomavirus 16/18 Genotype Triage in Cervical Cancer Screening. *Gynecol Oncol*. 2010 Nov; 119(2):237-42.

35. Bazan JG, Hara W, Hsu A, Kunz PA, Ford J, Fisher GA, Welton ML, Shelton A, Kapp DS, Koong AC, **Goodman KA**, Chang DT. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. *Cancer*. 2011 Aug 1;117(15):3342-51.
36. Fields RC, Strong VE, Gönen M, **Goodman KA**, Rizk NP, Kelsen DP, Ilson DH, Tang LH, Brennan MF, Coit DG, Shah MA. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastroesophageal adenocarcinoma. *Br J Cancer*. 2011 Jun 7;104(12):1840-7.
37. Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, Fisher GA, Kunz PL, Van Dam J, Quon A, Desser TS, Norton J, Hsu A, Maxim PG, Xing L, **Goodman KA**, Chang DT, Koong AC. Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer. *Int J Radiat Oncol Biol Phys*. 2011 81(1): 181-8.
38. Wright JL, Gollub MJ, Weiser MR, Saltz LB, Wong WD, Paty PB, Temple LK, Guillem JG, Minsky BD, **Goodman KA**. Surgery and High Dose Rate Intra-operative Radiation Therapy for Recurrent Squamous Cell Carcinoma of the Anal Canal. *Dis Colon Rectum*, 2011 Sep;54(9):1090-7.
39. Peng J, Shi D, **Goodman KA**, Goldstein D, Xiao C, Guan Z, Cai S. Early results of quality of life for curatively treated rectal cancers in Chinese patients with EORTC QLQ-CR29. *Radiat Oncol*. 2011 Aug 12;6:93.
40. Bickenbach KA, Gonen M, Tang LH, O'Reilly E, **Goodman K**, Brennan MF, D'Angelica MI, Dematteo RP, Fong Y, Jarnagin WR, Allen PJ. Downstaging in Pancreatic Cancer: A Matched Analysis of Patients Resected Following Systemic Treatment of Initially Locally Unresectable Disease. *Ann Surg Oncol*. 2012 May;19(5):1663-9.
41. Gollub MJ, Gultekin DH, Akin O, Do RK, Fuqua JL 3rd, Gonen M, Kuk D, Weiser M, Saltz L, Schrag D, **Goodman K**, Paty P, Guillem J, Nash GM, Temple L, Shia J, Schwartz LH. Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. *Eur Radiol*. 2011 Apr;22(4):821-31.
42. Kole TP, Aghayere O, Kwah J, Yorke ED, **Goodman KA**. Comparison of Heart and Coronary Artery Doses Associated with Intensity-Modulated Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Distal Esophageal Cancer. *Int J Radiat Oncol Biol Phys*. 2012 Aug 1;83(5):1580-6.
43. Ibarra RA, Rojas D, Snyder L, Yao M, Fabien J, Milano M, Katz A, **Goodman K**, Stephans K, El-Gazzaz G, Aucejo F, Miller C, Fung J, Lo S, Machtay M, Sanabria JR. Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors. *Acta Oncol*. 2012 May;51(5):575-83.
44. Milgrom SA, **Goodman KA**. The role of radiation therapy in the management of adrenal carcinoma and adrenal metastases. *J Surg Oncol*. 2012 Oct 1;106(5):647-50.

45. Butte JM, Gonen M, Ding P, **Goodman KA**, Allen PJ, Nash G, Guillem J, Paty PB, Saltz LB, Kemeny NE, Dematteo RP, Fong Y, Jarnagin WR, Weiser MR, D'Angelica MI. Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. *Cancer*. 2012 Nov 1; 118(21): 5414-23.
46. Alameddine R, Wehbe D, Weiser M, Segal N, **Goodman K**, Shamseddine A, Ang C, Haydar A, Sidani M, Geara F, Naghy M, O'Reilly EM, Abou-Alfa GK. Management of a locally advanced rectal cancer in a patient who declined surgery. *Gastrointest Cancer Res*. 2012 Nov; 5(6): 205-9
47. Liu F, Hu Y, Zhang Q, Kincaid R, **Goodman KA**, Mageras GS. Evaluation of deformable image registration and a motion model in CT images with limited features. *Phys Med Biol*. 2012 May 7;57(9):2539-54.
48. **Goodman KA**, Regine WF, Dawson LA, Ben-Josef E, Haustermans K, Bosch WR, Turian J, Abrams RA. Radiation therapy oncology group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer. *Int J Radiat Oncol Biol Phys*. 2012 Jul 1;83(3):901-8.
49. Ding P, Liska D, Tang P, Shia J, Saltz L, **Goodman K**, Downey RJ, Nash GM, Temple LK, Paty PB, Guillem JG, Wong WD, Weiser MR. Pulmonary recurrence predominates after combined modality therapy for rectal cancer: an original retrospective study. *Ann Surg*. 2012 Jul;256(1):111-6.
50. Flores LT, Bennett AV, Law EB, Hajj C, Griffith MP, **Goodman KA**. Patient-Reported Outcomes vs. Clinician Symptom Reporting During Chemoradiation for Rectal Cancer. *Gastrointest Cancer Res*. 2012 Jul;5(4):119-24.
51. Kim HJ, Boland PJ, Meredith DS, Lis E, Zhang Z, Shi W, Yamada YJ, **Goodman KA**. Fractures of the sacrum after chemoradiation for rectal carcinoma: incidence, risk factors, and radiographic evaluation. *Int J Radiat Oncol Biol Phys*. 2012 Nov 1;84(3):694-9.
52. Minn AY, Riedel E, Halpern J, Johnston LJ, Horning SJ, Hoppe RT, **Goodman KA**. Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma. *Br J Haematol*. 2012 Nov;159(3):329-39.
53. Smith JD, Ruby JA, **Goodman KA**, Saltz LB, Guillem JG, Weiser MR, Temple LK, Nash GM, Paty PB. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. *Ann Surg*. 2012 Dec;256(6):965-72.
54. Morikawa LK, Zelefsky MJ, Cohen GN, Zaider M, Chiu J, Mathur N, Worman MF, **Goodman KA**. Intraoperative high-dose-rate brachytherapy using dose painting technique: Evaluation of safety and preliminary clinical outcomes. *Brachytherapy*. 2013 Jan-Feb;12(1):1-7.
55. An X, Lin X, Wang FH, **Goodman K**, Cai PQ, Kong LH, Fang YJ, Gao YH, Lin JZ, Wan DS, Pan ZZ, Ding PR. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: A meta analysis. *Eur J Cancer*. 2013 Mar;49(4):843-51.

56. Gollub MJ, Maas M, Weiser M, Beets GL, **Goodman K**, Berkers L, Beets-Tan RG. Recognition of the anterior peritoneal reflection at rectal MRI. *AJR Am J Roentgenol*. 2013 Jan;200(1):97-101.
57. Desai NB, Stein NF, Laquaglia MP, Alektiar KM, Kushner BH, Modak S, Magnan HM, **Goodman K**, Wolden SL. Reduced Toxicity with Intensity Modulated Radiation Therapy (IMRT) for Desmoplastic Small Round Cell Tumor (DSRCT): An Update on the Whole Abdominopelvic Radiation Therapy (WAP-RT) Experience. *Int J Radiat Oncol Biol Phys*. 2013 Jan 1;85(1):e67-72.
58. Berber B, Ibarra R, Snyder L, Yao M, Fabien J, Milano MT, Katz AW, **Goodman K**, Stephans K, El-Gazzaz G, Aucejo F, Miller C, Fung J, Lo S, Machtay M, Sanabria J. Multicentre results of stereotactic body radiotherapy for secondary liver tumours. *HPB (Oxford)*. 2013 Jan 14.
59. Araujo RL, Gaujoux S, Huguet F, Gonen M, D'Angelica MI, Dematteo RP, Fong Y, Kingham TP, Jarnagin WR, **Goodman KA**, Allen PJ. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis. *HPB (Oxford)*. 2013 Jan 10.
60. **Goodman KA**, Khalid N, Kachnic LA, Minsky BD, Crozier C, Owen JB, Devlin PM, Thomas CR Jr. Quality Research in Radiation Oncology analysis of clinical performance measures in the management of gastric cancer. *Int J Radiat Oncol Biol Phys*. 2013 Feb 1;85(2):355-62.
61. Folkert MR, Cohen GN, Wu AJ, Gerdes H, Schattner MA, Markowitz AJ, Ludwig E, Ilson DH, Bains MS, Zelefsky MJ, **Goodman KA**. Endoluminal high-dose-rate brachytherapy for early stage and recurrent esophageal cancer in medically inoperable patients. *Brachytherapy*. 2013 Sep-Oct;12(5):463-70.
62. Katsoulakis E, Riaz N, Cannon DM, **Goodman K**, Spratt DE, Lovelock M, Yamada Y. Image-guided Radiation Therapy for Liver Tumors: Gastrointestinal Histology Matters. *Am J Clin Oncol*. 2014 Dec;37(6):561-7.
63. **Goodman KA**. Quality assurance for radiotherapy: a priority for clinical trials. *J Natl Cancer Inst*. 2013 Mar 20;105(6):376-7.
64. Kincaid RE, Yorke ED, **Goodman KA**, Rimner A, Wu AJ, Mageras GS. Investigation of gated cone-beam CT to reduce respiratory motion blurring. *Med Phys*. 2013 Apr;40(4):041717.
65. Trakarnsanga A, Gonen M, Shia J, **Goodman KA**, Nash GM, Temple LK, Guillem JG, Paty PB, Garcia-Aguilar J, Weiser MR. What is the significance of the circumferential margin in locally advanced rectal cancer after neoadjuvant chemoradiotherapy? *Ann Surg Oncol*. 2013 Apr;20(4):1179-84.
66. McNamara JE, Regmi R, Michael Lovelock D, Yorke ED, **Goodman KA**, Rimner A, Mostafavi H, Mageras GS. Toward correcting drift in target position during radiotherapy via computer-controlled couch adjustments on a programmable Linac. *Med Phys*. 2013 May;40(5):051719.

67. Dasgupta T, Rothenstein D, Chou JF, Zhang Z, Wright JL, Saltz LB, Temple LK, Paty PB, Weiser MR, Guillem JG, Nash GM, **Goodman KA**. Intensity-modulated radiotherapy vs conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. *Radiother Oncol*. 2013 May; 107 (2): 189-94.
68. Hajj C, **Goodman K**, Kelsen D, Shia J, Shamseddine A, Naghy M, Sidani M, Eloubeidi M, Merhi F, Geara F, Ang C, Saltz, L, Abou-Alfa GK. A 40-year-old woman with locally advanced rectal cancer and a solitary liver metastasis. *Gastrointest Cancer Res*. 2013 May; 6(3):87-9.
69. Gerber N, Ilson DH, Wu AJ, Janjigian YY, Kelsen DP, Zheng J, Zhang Z, Bains MS, Rizk N, Rusch VW, **Goodman KA**. Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma. *Dis Esophagus*. 2014 Apr;27(3):235-41.
70. Yang TJ, Oh JH, Son CH, Apte A, Deasy JO, Wu A, **Goodman KA**. Predictors of Acute Gastrointestinal Toxicity During Pelvic Chemoradiotherapy in Patients With Rectal Cancer. *Gastrointest Cancer Res*. 2013 Sep; 6 (5-6): 129-136.
71. Milgrom SA, Vargas HA, Sala E, Kelvin JF, Hricak H, **Goodman KA**. Acute effects of pelvic irradiation on the adult uterus revealed by dynamic contrast enhanced MRI. *Br J Radiol*. 2013 Nov; 86.
72. Lovelock DM, Zatzky J, **Goodman K**, Yamada Y. The effectiveness of a pneumatic compression belt in reducing respiratory motion of abdominal tumors in patients undergoing stereotactic body radiotherapy. *Technol Cancer Res Treat*. 2014 Jun;13(3):259-67
73. Cuaron JJ, **Goodman KA**, Lee N, Wu AJ. External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors. *Radiat Oncol*. 2013 Nov 23;8 (1):274.
74. Gollub MJ, Cao K, Gultekin DH, Kuk D, Gonen M, Sogn M, Schwartz LH, Weiser MR, Temple LK, Nash GM, Guillem JG, Wang M, Garcia-Aguilar J, **Goodman K**, Paty PB. Prognostic Aspects of DCE-MRI in Recurrent Rectal Cancer. *Euro Radiol*. 2013 Dec; 23 (12): 3336-44.
75. Dikken JL, Coit DG, Baser RE, Gönen M, **Goodman KA**, Brennan MF, Jansen EP, Boot H, van de Velde CJ, Cats A, Verheij M. Performance of a nomogram predicting disease-specific survival after an R0 resection for gastric cancer in patients receiving postoperative chemoradiation therapy. *Int J Radiat Oncol Biol Phys*. 2014 Mar 1;88(3):624-9.
76. Schrag D, Weiser MR, **Goodman KA**, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LK, Paty PB, Saltz LB. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. *J Clin Oncol*. 2014 Feb 20;32(6):513-8.
77. Reyngold M, Niland J, ter Veer A, Milne D, Bekaii-Saab T, Cohen SJ, Lai L, Schrag D, Skibber JM, Small W Jr, Weiser M, Wilkinson N, **Goodman KA**. Neoadjuvant radiotherapy use in locally advanced rectal cancer at NCCN member institutions. *J Natl Compr Canc Netw*. 2014 Feb;12(2):235-43.

78. Milgrom SA, **Goodman KA**, Nash GM, Paty PB, Guillem JG, Temple LK, Weiser MR, Garcia-Aguilar J. Neoadjuvant Radiation Therapy Prior to Total Mesorectal Excision for Rectal Cancer is Not Associated with Postoperative Complications Using Current Techniques. *Ann Surg Oncol*. 2014 Jul;21(7):2295-302.
79. Wild AT, Chang DT, **Goodman KA**, Laheru DA, Zheng L, Raman SP, Columbo LA, Wolfgang CL, Koong AC, Herman JM. A Phase 2 Multi-institutional Study to Evaluate Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable, Locally Advanced Pancreatic Adenocarcinoma. *Pract Radiat Oncol*. 2013 Apr-Jun;3(2 Suppl 1):S4-5.
80. Cercek A, **Goodman KA**, Hajj C, Weisberger E, Segal NH, Reidy-Lagunes DL, Stadler ZK, Wu AJ, Weiser MR, Paty PB, Guillem JG, Nash GM, Temple LK, Garcia-Aguilar J, Saltz LB. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. *J Natl Compr Canc Netw*. 2014 Apr;12(4):513-9.
81. Smith JD, Reidy DL, **Goodman KA**, Shia J, Nash GM. A Retrospective Review of 126 High-Grade Neuroendocrine Carcinomas of the Colon and Rectum. *Ann Surg Oncol*. 2014 Sep;21(9):2956-62.
82. Jabbour SK, Hashem SA, Bosch W, Kim TK, Finkelstein SE, Anderson BM, Ben-Josef E, Crane CH, **Goodman KA**, Haddock MG, Herman JM, Hong TS, Kachnic LA, Mamon HJ, Pantarotto JR, Dawson LA. Upper abdominal normal organ contouring guidelines and atlas: A Radiation Therapy Oncology Group consensus. *Pract Radiat Oncol*. 2014 Mar-Apr;4(2):82-9.
83. Wong AC, Stock S, Schrag D, Kahn KL, Salz T, Charlton ME, Rogers SO Jr, **Goodman KA***, Keating NL*. Physicians' beliefs about the benefits and risks of adjuvant therapies for stage II and stage III colorectal cancer. *J Oncol Pract*. 2014 Sep;10(5):e360-7.
84. Regmi R, Lovelock DM, Hunt M, Zhang P, Pham H, Xiong J, Yorke ED, **Goodman KA**, Rimner A, Mostafavi H, Mageras GS. Automatic tracking of arbitrarily shaped implanted markers in kilovoltage projection images: a feasibility study. *Med Phys*. 2014 Jul;41(7):071906.
85. Trakarnsanga A, Gönen M, Shia J, Nash GM, Temple LK, Guillem JG, Paty PB, **Goodman KA**, Wu A, Gollub M, Segal N, Saltz L, Garcia-Aguilar J, Weiser MR. Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment. *J Natl Cancer Inst*. 2014 Sep 22;106(10).
86. Yang TJ, Oh JH, Apte A, Son CH, Deasy JO, **Goodman KA**. Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy. *Radiother Oncol*. 2014 Oct;113(1):29-34.
87. Li G, Caraveo M, Wei J, Rimner A, Wu AJ, **Goodman KA**, Yorke E. Rapid estimation of 4DCT motion-artifact severity based on 1D breathing-surrogate periodicity. *Med Phys*. 2014 Nov;41(11):111717.

88. Herman JM, Chang DT, **Goodman KA**, Dholakia AS, Raman SP, Hacker-Prietz A, Iacobuzio-Donahue CA, Griffith ME, Pawlik TM, Pai JS, O'Reilly E, Fisher GA, Wild AT, Rosati LM, Zheng L, Wolfgang CL, Laheru DA, Columbo LA, Sugar EA, Koong AC. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. *Cancer*. 2014 Dec 23.
89. Terezakis S, Morikawa L, Wu A, Zhang Z, Shi W, Weiser MR, Paty PB, Guillem J, Temple L, Nash GM, Zelefsky MJ, **Goodman KA**. Long-Term Survival After High-Dose-Rate Brachytherapy for Locally Advanced or Recurrent Colorectal Adenocarcinoma. *Ann Surg Oncol*. 2015 Jan 29.
90. Huguet F, Yorke ED, Davidson M, Zhang Z, Jackson A, Mageras GS, Wu AJ, **Goodman KA**. Modeling pancreatic tumor motion using 4-dimensional computed tomography and surrogate markers. *Int J Radiat Oncol Biol Phys*. 2015 Mar 1;91(3):579-87.
91. Salz T, Baxi SS, Raghunathan N, Onstad EE, Freedman AN, Moskowitz CS, Dalton SO, **Goodman KA**, Johansen C, Matasar MJ, de Nully Brown P, Oeffinger KC, Vickers AJ. Are we ready to predict late effects? A systematic review of clinically useful prediction models. *Eur J Cancer*. 2015 Apr;51(6):758-66.
92. Son CH, Law E, Oh JH, Apte AP, Yang TJ, Riedel E, Wu AJ, Deasy JO, **Goodman KA**. Dosimetric Predictors of Radiation-Induced Vaginal Stenosis After Pelvic Radiation Therapy for Rectal and Anal Cancer. *Int J Radiat Oncol Biol Phys*. 2015 Jul 1;92(3):548-54.
93. Regmi R, Lovelock DM, Zhang P, Pham H, Xiong J, Yorke ED, **Goodman KA**, Wu AJ, Mageras GS. Intrafractional changes in time lag relationship between anterior-posterior external and superior-inferior internal motion signals in abdominal tumor sites. *Med Phys*. 2015 Jun;42(6):2813-7.
94. Law E, Kelvin JF, Thom B, Riedel E, Tom A, Carter J, Alektiar KM, **Goodman KA**. Prospective study of vaginal dilator use adherence and efficacy following radiotherapy. *Radiother Oncol*. 2015 Jul;116(1):149-55.
95. Wu AJ, Bosch WR, Chang DT, Hong TS, Jabbour SK, Kleinberg LR, Mamon HJ, Thomas CR Jr, **Goodman KA**. Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer. *Int J Radiat Oncol Biol Phys*. 2015 Jul 15;92(4):911-20.
96. Sadot E, Doussot A, O'Reilly EM, Lowery MA, **Goodman KA**, Do RK, Tang LH, Gönen M, D'Angelica MI, DeMatteo RP, Kingham TP, Jarnagin WR, Allen PJ. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. *Ann Surg Oncol*. 2015 Oct;22(11):3512-21.
97. Julie DA, Oh JH, Apte AP, Deasy JO, Tom A, Wu AJ, **Goodman KA**. Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. *Acta Oncol*. 2016 Feb;55(2):208-16.
98. Russo S, Blackstock AW, Herman JM, Abdel-Wahab M, Azad N, Das P, **Goodman KA**, Hong TS, Jabbour SK, Jones WE 3rd, Konski AA, Koong AC, Kumar R, Rodriguez-Bigas M,

- Small W Jr, Thomas CR Jr, Suh WW. ACR Appropriateness Criteria® Local Excision in Early Stage Rectal Cancer. *Am J Clin Oncol*. 2015 Oct;38(5):520-5.
99. Yorke E, Xiong Y, Han Q, Zhang P, Mageras G, Lovelock M, Pham H, Xiong JP, **Goodman KA**. Kilovoltage Imaging of Implanted Fiducials to Monitor Intrafraction Motion With Abdominal Compression During Stereotactic Body Radiation Therapy for Gastrointestinal Tumors. *Int J Radiat Oncol Biol Phys*. 2015 Nov 18.
100. Chhabra A, Ong LT, Kuk D, Ku G, Ilson D, Janjigian YY, Wu A, Schöder H, **Goodman KA**. Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. *Br J Cancer*. 2015 Dec 22;113(12):1658-65.
101. Chargari C, **Goodman KA**, Diallo I, Guy JB, Rancoule C, Cosset JM, Deutsch E, Magne N. Risk of second cancers in the era of modern radiation therapy: does the risk/benefit analysis overcome theoretical models? *Cancer Metastasis Rev*. 2016 Jun;35(2):277-88.
102. Prasad S, Cambridge L, Huguet F, Chou JF, Zhang Z, Wu AJ, O'Reilly EM, Allen PJ, **Goodman KA**. Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer. *Pract Radiat Oncol*. 2016 Mar-Apr;6(2):78-85. doi: 10.1016/j.prro.2015.09.006. Epub 2015 Sep 25.
103. Call JA, Prendergast BM, Jensen LG, Ord CB, **Goodman KA**, Jacob R, Mell LK, Thomas CR Jr, Jabbour SK, Miller RC. Intensity-modulated Radiation Therapy for Anal Cancer: Results From a Multi-Institutional Retrospective Cohort Study. *Am J Clin Oncol*. 2016 Feb;39(1):8-12.
104. Hötker AM, Tarlinton L, Mazaheri Y, Woo KM, Gönen M, Saltz LB, **Goodman KA**, Garcia-Aguilar J, Gollub MJ. Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters. *Eur Radiol*. 2016 Mar 5. [Epub ahead of print]
105. **Goodman KA**, Patton CE, Fisher GA, Hoffe SE, Haddock MG, Parikh PJ, Kim J, Baxter NN, Czito BG, Hong TS, Herman JM, Crane CH, Hoffman KE. Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method. *Pract Radiat Oncol*. 2016 May-Jun;6(3):166-75.
106. Kelvin JF, Thom B, Benedict C, Carter J, Corcoran S, Dickler MN, **Goodman KA**, Margolies A, Matasar MJ, Noy A, Goldfarb SB. Cancer and Fertility Program Improves Patient Satisfaction With Information Received. *J Clin Oncol*. 2016 May 20;34(15):1780-6.
107. Ku GY, Kriplani A, Janjigian YY, Kelsen DP, Rusch VW, Bains M, Chou J, Capanu M, Wu AJ, **Goodman KA**, Ilson DH. Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. *Cancer*. 2016 Jul 1;122(13):2083-90.
108. Liu F, Ng S, Huguet F, Yorke ED, Mageras GS, **Goodman KA**. Are fiducial markers useful surrogates when using respiratory gating to reduce motion of gastroesophageal junction tumors? *Acta Oncol*. 2016 Aug;55(8):1040-6.

Karyn A. Goodman, MD, MS

109. Jackson MW, Amini A, Jones BL, Rusthoven CG, Schefter TE, **Goodman KA**. Treatment Selection and Survival Outcomes With and Without Radiation for Unresectable, Localized Intrahepatic Cholangiocarcinoma. *Cancer J*. 2016 Jul-Aug;22(4):237-42.
110. Rao AD, Sugar EA, Chang DT, **Goodman KA**, Hacker-Prietz A, Rosati LM, Columbo L, O'Reilly E, Fisher GA, Zheng L, Pai JS, Griffith ME, Laheru DA, Iacobuzio-Donahue CA, Wolfgang CL, Koong A, Herman JM. Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. *Pract Radiat Oncol*. 2016 May 25. [Nov - Dec;6(6):417-424
111. Amini A, Jones BL, Ghosh D, Schefter TE, **Goodman KA**. Impact of facility volume on outcomes in patients with squamous cell carcinoma of the anal canal: Analysis of the National Cancer Data Base. *Cancer*. 2016 Aug 29. [Epub ahead of print]
112. Ng SY, Colborn KL, Cambridge L, Hajj C, Yang TJ, Wu AJ, **Goodman KA**. Acute toxicity with intensity modulated radiotherapy versus 3-dimensional conformal radiotherapy during preoperative chemoradiation for locally advanced rectal cancer. *Radiother Oncol*. 2016 Nov;121(2):252-257.
113. Huguet F, Hajj C, Winston CB, Shi W, Zhang Z, Wu AJ, O'Reilly EM, Reidy DL, Allen P, **Goodman KA**. Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection. *Acta Oncol*. 2017;56(3):384-390.
114. Garcia B, **Goodman KA**, Cambridge L, Dunphy M, Wu AJ. Distribution of FDG-avid nodes in esophageal cancer: implications for radiotherapy target delineation. *Radiat Oncol*. 2016 Nov 25;11(1):156.
115. Sioulas VD, Jorge S, Chern JY, Schiavone MB, Weiser MR, Kelvin JF, Gardner GJ, Sonoda Y, Abu-Rustum NR, **Goodman KA**, Leitao MM Jr. Robotically Assisted Laparoscopic Ovarian Transposition in Women with Lower Gastrointestinal Cancer Undergoing Pelvic Radiotherapy. *Ann Surg Oncol*. 2016 Nov 9. [Epub ahead of print]
116. Ku GY, Bains MS, Park DJ, Janjigian YY, Rusch VW, Rizk NP, Yoon SS, Millang B, Capanu M, **Goodman KA**, Ilson DH. Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. *J Gastrointest Oncol*. 2016 Dec;7(6):828-837
117. Smith JJ, Wasserman I, Milgrom SA, Chow OS, Chen CT, Patil S, **Goodman KA**, Garcia-Aguilar J. Single Nucleotide Polymorphism TGFβ1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. *Int J Radiat Oncol Biol Phys*. 2017 Apr 1;97(5):924-93.
118. Stumpf PK, Amini A, Jones BL, Koshy M, Sher DJ, Lieu CH, Schefter TE, **Goodman KA**, Rusthoven CG. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis. *Cancer*. 2017 Sep 1;123(17):3402-3409.
119. **Goodman KA**, Julie D, Cercek A, Cambridge L, Woo KM, Zhang Z, Wu AJ, Reidy DL, Segal NH, Stadler ZK, Saltz LB. Capecitabine With Mitomycin Reduces Acute Hematologic

- Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer. *Int J Radiat Oncol Biol Phys*. 2017 Aug 1;98(5):1087-1095.
120. Amini A, Jones BL, Stumpf P, Leong S, Lieu CH, Weekes C, Davis SL, Messersmith WA, Purcell WT, Ghosh D, Schefter T, **Goodman KA**. Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database. *Pancreas*. 2017 Aug;46(7):904-912
121. Park JJ, Hajj C, Reyngold M, Shi W, Zhang Z, Cuaron JJ, Crane CH, O'Reilly EM, Lowery MA, Yu KH, **Goodman KA**, Wu AJ. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. *Acta Oncol*. 2017 Jun 29:1-8. [Epub ahead of print]
122. Campbell WG, Jones BL, Schefter T, **Goodman KA**, Miften M. An evaluation of motion mitigation techniques for pancreatic SBRT. *Radiother Oncol*. 2017 Jul;124(1):168-173.
123. Hajj C, Russell J, Hart CP, **Goodman KA**, Lowery MA, Haimovitz-Friedman A, Deasy JO, Humm JL. A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model. *Transl Oncol*. 2017 Oct;10(5):760-765.
124. Campbell WG, Miften M, Olsen L, Stumpf P, Schefter T, **Goodman KA**, Jones BL. Neural network dose models for knowledge-based planning in pancreatic SBRT. *Med Phys*. 2017 Dec;44(12):6148-58.
125. Tom A, Bennett AV, Rothenstein D, Law E, **Goodman KA**. Prevalence of patient-reported gastrointestinal symptoms and agreement with clinician toxicity assessments in radiation therapy for anal cancer. *Qual Life Res*. 2018 Jan;27(1):97-103.
126. Reyngold M, Niland J, Ter Veer A, Bekaii-Saab T, Lai L, Meyer JE, Nurkin SJ, Schrag D, Skibber JM, Benson AB, Weiser MR, Crane CH, **Goodman KA**. Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers. *Adv Radiat Oncol*. 2017 Oct 12;3(1):34-41.
127. Wee CW, Kang HC, Wu HG, Chie EK, Choi N, Park JM, Kim JI, Huang CM, Wang JY, Ng SY, **Goodman KA**. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in rectal cancer treated with neoadjuvant concurrent chemoradiation: a meta-analysis and pooled-analysis of acute toxicity. *Jpn J Clin Oncol*. 2018 May 1;48(5):458-466.
128. Chapman BC, Gleisner A, Rigg D, Meguid C, **Goodman K**, Brauer B, Gajdos C, Schulick RD, Edil BH, McCarter MD. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma. *J Surg Oncol*. 2018 Feb 15. [Epub ahead of print]
129. Taggar AS, Pitter KL, Cohen GN, Schattner M, Gerdes H, Markowitz AJ, Ilson D, Brady P, Cuaron JJ, **Goodman KA**, Wu AJ. Endoluminal high-dose-rate brachytherapy for locally recurrent or persistent esophageal cancer. *Brachytherapy*. 2018 May - Jun;17(3):621-627.

Karyn A. Goodman, MD, MS

130. Miften M, Vinogradskiy Y, Moiseenko V, Grimm J, Yorke E, Jackson A, Tomé WA, Ten Haken RK, Ohri N, Méndez Romero A, **Goodman KA**, Marks LB, Kavanagh B, Dawson LA. Radiation Dose-Volume Effects for Liver SBRT. *Int J Radiat Oncol Biol Phys*. 2018 Jan 6. [Epub ahead of print].
131. Kincaid RE Jr, Hertanto AE, Hu YC, Wu AJ, **Goodman KA**, Pham HD, Yorke ED, Zhang Q, Chen Q, Mageras GS. Evaluation of respiratory motion-corrected cone-beam CT at end expiration in abdominal radiotherapy sites: a prospective study. *Acta Oncol*. 2018 Aug;57(8):1017-24.
132. Ghoreishi Z, Keshavarz S, Asghari Jafarabadi M, Fathifar Z, **Goodman KA**, Esfahani A. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. *BMC Cancer*. 2018 Oct 5;18(1):958.
133. Vinogradskiy Y, **Goodman KA**, Schefter T, Miften M, Jones BL. The clinical and dosimetric impact of real-time target tracking in pancreatic SBRT. *Int J Radiat Oncol Biol Phys*. 2019 Jan 1;103(1):268-275
134. Chapman BC, **Goodman K**, Hosokawa P, Gleisner A, Cowan ML, Birnbaum E, Vogel JD. Improved survival in rectal cancer patients who are treated with long-course versus short-course neoadjuvant radiotherapy: A propensity-matched analysis of the NCDB. *J Surg Oncol*. 2019 Mar;119(4):518-531.
135. Greally M, Chou JF, Molena D, Rusch VW, Bains MS, Park BJ, Wu AJ, **Goodman KA**, Kelsen DP, Janjigian YY, Ilson DH, Ku GY. Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders. *J Thorac Oncol*. 2019; 14(3):540-546.
136. Ben-Aharon I, Elkabets M, Pelossof R, Yu KH, Iacobuzio-Donahue CA, Leach SD, Lowery MA, **Goodman KA**, O'Reilly EM. Genomic Landscape of Pancreatic Adenocarcinoma in Younger vs Older Patients: Does Age Matter? *Clin Cancer Res*. 2019 Apr 1;25(7):2185-2193.
137. Shinde A, Verma V, Li R, Glaser S, Raoof M, Warner SG, Chung V, Singh G, Chen YJ, **Goodman KA**, Amini A. The role of sequential radiation following adjuvant chemotherapy in resected pancreatic cancer. *J Gastrointest Oncol*. 2019 Jun;10(3):462-473.
138. Ng SY, Colborn KL, Cambridge L, Cercek A, Reidy-Lagunes DL, Segal N, Stadler Z, Saltz LB, Paty PB, Guillem J, Weiser MR, Nash G, Garcia-Aguilar J, **Goodman KA**. Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer. *Clin Colorectal Cancer*. 2019;18(3):167-174.
139. Machicado JD, Obuch JC, **Goodman KA**, Schefter TE, Frakes J, Hoffe S, Latifi K, Simon VC, Santangelo T, Ezekwe E, Edmundowicz SA, Brauer BC, Shah RJ, Hammad HT, Wagh MS, Attwell A, Han S, Klapman J, Wani S. Endoscopic Ultrasound Placement of Preloaded Fiducial Markers Shortens Procedure Time Compared to Back-Loaded Markers. *Clin Gastroenterol Hepatol*. 2019 Apr 28. [Epub ahead of print]

Karyn A. Goodman, MD, MS

140. Ding Y, Campbell WG, Miften M, Vinogradskiy Y, **Goodman KA**, Schefter T, Jones BL. Quantifying Allowable Motion to Achieve Safe Dose Escalation in Pancreatic SBRT. *Pract Radiat Oncol*. 2019 Jul - Aug;9(4):e432-e442.
141. Lennon S, Oweida A, Milner D, Phan AV, Bhatia S, Van Court B, Darragh L, Mueller AC, Raben D, Martínez-Torrecedrada JL, Pitts TM, Somerset H, Jordan KR, Hansen KC, Williams J, Messersmith WA, Schulick RD, Owens P, **Goodman KA**, Karam SD. Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination. *Clin Cancer Res*. 2019 Jun 1;25(11):3352-3365.
142. Oar A, Lee M, Le H, Hruby G, Dalfsen R, Pryor D, Lee D, Chu J, Holloway L, Briggs A, Barbour A, Chander S, Ng SP, Samra J, Shakeshaft J, Goldstein D, Nguyen N, **Goodman KA**, Chang DT, Kneebone A. Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). *Pract Radiat Oncol* 2019;10(3):e136-e146.
143. Abrams RA, Winter KA, Safran H, **Goodman KA**, Regine WF, Berger AC, Gillin MT, Philip PA, Lowy AM, Wu A, DiPetrillo TA, Corn BW, Seaward SA, Haddock MG, Song S, Jiang Y, Fisher BJ, Katz AW, Mehta S, Willett CG, Crane CH. Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial. *Am J Clin Oncol*. 2020;43(3):173-179.
144. Cercek A, Dos Santos Fernandes G, Roxburgh CS, Ganesh K, Ng S, Sanchez-Vega F, Yaeger R, Segal NH, Reidy-Lagunes DL, Varghese AM, Markowitz A, Wu C, Szeglin B, Sauv e CG, Salo-Mullen E, Tran C, Patel Z, Krishnan A, Tkachuk K, Nash GM, Guillem J, Paty PB, Shia J, Schultz N, Garcia-Aguilar J, Diaz LA, **Goodman K**, Saltz LB, Weiser MR, Smith JJ, Stadler ZK.
145. Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. *Clin Cancer Res*. 2020 Jul 1;26(13):3271-3279.
146. Kinh Do R, Reyngold M, Paudyal R, Oh JH, Konar AS, LoCastro E, **Goodman KA**, Shukla-Dave A. Diffusion-Weighted and Dynamic Contrast-Enhanced MRI Derived Imaging Metrics for Stereotactic Body Radiotherapy of Pancreatic Ductal Adenocarcinoma: Preliminary Findings. *Tomography*. 2020 Jun;6(2):261-271.
147. Mahadevan A, Moningi S, Grimm J, Li XA, Forster KM, Palta M, Prior P, **Goodman KA**, Narang A, Heron DE, Lo SS, Urbanic J, Herman JM. Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer. *Int J Radiat Oncol Biol Phys*. 2020 Dec 24:S0360-3016(20)34539-9.
148. Zakem SJ, Mueller AC, Meguid C, Torphy RJ, Holt DE, Schefter T, Messersmith WA, McCarter MD, Del Chiaro M, Schulick RD, **Goodman KA**. Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer. *HPB (Oxford)*. 2020 Jul;23(7):1072-1083.

149. Moskalenko M, Zaccone J, Fiscelli CA, Wieworka J, Anderson R, Choflet A, Martens S, **Goodman KA**, Golden DW, Nath SK. Assessment of Radiation Oncology Nurse Education in the United States. *Int J Radiat Oncol Biol Phys*. 2021 Jul 1;110(3):667-671.
150. Mueller AC, Piper M, Goodspeed A, Bhuvane S, Williams JS, Bhatia S, Phan AV, Van Court B, Zolman KL, Peña B, Oweida AJ, Zakem S, Meguid C, Knitz MW, Darragh L, Bickett TE, Gadwa J, Mestroni L, Taylor MRG, Jordan KR, Dempsey P, Lucia MS, McCarter MD, Chiaro MD, Messersmith WA, Schulick RD, **Goodman KA**, Gough MJ, Greene CS, Costello JC, Neto AG, Lagares D, Hansen KC, Van Bokhoven A, Karam SD. Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. *Cancer Res*. 2021 Jun 15;81(12):3255-3269.
151. Kastelowitz N, Marsh MD, McCarter M, Meguid RA, Bhardwaj NW, Mitchell JD, Weyant MJ, Scott C, Schefter T, Stumpf P, Leong S, Messersmith W, Lieu C, Leal AD, Davis SL, Purcell WT, Kane M, Wani S, Shah R, Hammad H, Edmundowicz S, **Goodman KA**. Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers. *Front Oncol*. 2021 Mar 10;11:614640.
152. Stumpf PK, Yorke ED, El Naqa I, Cuneo KC, Grimm J, **Goodman KA**. Modeling of Tumor Control Probability in Stereotactic Body Radiation Therapy for Adrenal Tumors. *Int J Radiat Oncol Biol Phys*. 2021;110(1):217-226.
153. Mahadevan A, Moningi S, Grimm J, Li XA, Forster KM, Palta M, Prior P, **Goodman KA**, Narang A, Heron DE, Lo SS, Urbanic J, Herman JM. Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer. *Int J Radiat Oncol Biol Phys*. 2021 May 1;110(1):206-216.
154. Ho F, Torphy RJ, Friedman C, Leong S, Kim S, Wani S, Schefter T, Scott CD, Mitchell JD, Weyant MJ, Meguid RA, Gleisner AL, **Goodman KA**, McCarter MD. Induction Chemotherapy Plus Neoadjuvant Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma. *Ann Surg Oncol*. 2021 Nov;28(12):7208-7218.
155. Marshall DC, Ghiassi-Nejad Z, Powers A, Reidenberg JS, Argiriadi P, Ru M, Dumane V, Buckstein M, **Goodman K**, Blank SV, Schnur J, Rosenstein B. A first radiotherapy application of functional bulbocrotoris anatomy, a novel female sexual organ-at-risk, and organ-sparing feasibility study. *Br J Radiol*. 2021. Online ahead of print.
156. Oba A, Wu YHA, Lieu CH, Meguid C, Colborn KL, Beaty L, Al-Musawi MH, Davis SL, Leal AD, Purcell T, King G, Wooten ES, Fujiwara Y, **Goodman KA**, Schefter T, Karam SD, Gleisner AL, Ahrendt S, Leong S, Messersmith WA, Schulick RD, Del Chiaro M. Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. *Br J Surg*. 2021 Aug 19;108(8):976-982.
157. Goodman KA, Ou FS, Hall NC, Bekaii-Saab T, Fruth B, Twohy E, Meyers MO, Boffa DJ, Mitchell K, Frankel WL, Niedzwiecki D, Noonan A, Janjigian YY, Thurmes PJ, Venook AP, Meyerhardt JA, O'Reilly EM, Ilson DH. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. *J Clin Oncol*. 2021;39(25):2803-2815.

158. Paudyal R, LoCastro E, Reyngold M, Do RK, Konar AS, Oh JH, Dave A, Yu K, **Goodman KA**, Shukla-Dave A. Longitudinal Monitoring of Simulated Interstitial Fluid Pressure for Pancreatic Ductal Adenocarcinoma Patients Treated with Stereotactic Body Radiotherapy. *Cancers (Basel)*. 2021;13(17):4319.
159. Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, Verheij FS, Omer DM, Lee M, Dunne RF, Marcet J, Cataldo P, Polite B, Herzig DO, Liska D, Oommen S, Friel CM, Ternent C, Coveler AL, Hunt S, Gregory A, Varma MG, Bello BL, Carmichael JC, Krauss J, Gleisner A, Paty PB, Weiser MR, Nash GM, Pappou E, Guillem JG, Temple L, Wei IH, Widmar M, Lin S, Segal NH, Cercek A, Yaeger R, Smith JJ, **Goodman KA**, Wu AJ, Saltz LB. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. *J Clin Oncol*. 2022;40(23):2546-2556.
160. Zakem SJ, Jones B, Castillo R, Castillo E, Miften M, **Goodman KA**, Schefter T, Olsen J, Vinogradskiy Y. Cardiac metabolic changes on 18 F-positron emission tomography after thoracic radiotherapy predict for overall survival in esophageal cancer patients. *J Appl Clin Med Phys*. 2022;Mar 4:e13552.
161. Jones BM, Rowley JP, Sindhu KK, Lehrer EJ, Hsieh K, Nehlsen AD, Green S, **Goodman KA**. Gender Differences in the Research Productivity of Radiation Oncology Resident Graduates in the United States: 2015 to 2019. *Adv Radiat Oncol*. 2022;8(2):101135.
162. Reyngold M, Karam SD, Hajj C, Wu AJ, Cuaron J, Lobaugh S, Yorke ED, Dickinson S, Jones B, Vinogradskiy Y, Shukla-Dave A, Do RKG, Sigel C, Zhang Z, Crane CH, **Goodman KA**. Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer. *Int J Radiat Oncol Biol Phys*. 2023 Mar 12:S0360-3016.
163. Moskalenko M, Jones BL, Mueller A, Lewis S, Shiao JC, Zakem SJ, Robin TP, **Goodman KA**. Fiducial Markers Allow Accurate and Reproducible Delivery of Liver Stereotactic Body Radiation Therapy. *Curr Oncol*. 2023;30(5):5054-5061.
164. Janczewski LM, Faski J, Nelson H, Gollub MJ, Eng C, Brierley JD, Palefsky JM, Goldberg RM, Washington MK, Asare EA, **Goodman KA**; American Joint Committee on Cancer Expert Panel on Cancers of the Lower Gastrointestinal, Anus Disease Site. Survival outcomes used to generate version 9 American Joint Committee on Cancer staging system for anal cancer. *CA Cancer J Clin*. 2023;73(5):516-523.
165. Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, Goldberg J, Al Baghdadi T, **Goodman KA**, McWilliams RR, Farma JM, George TJ, Kennecke HF, Shergill A, Montemurro M, Nelson GD, Colgrove B, Gordon V, Venook AP, O'Reilly EM, Meyerhardt JA, Dueck AC, Basch E, Chang GJ, Mamon HJ. Preoperative Treatment of Locally Advanced Rectal Cancer. *N Engl J Med*. 2023;389(4):322-334.
166. Tchelebi LT, Winter KA, Abrams RA, Safran HP, Regine WF, McNulty S, Wu A, Du KL, Seaward SA, Bian SX, Aljumaily R, Shivnani A, Knoble JL, Crocenzi TS, DiPetrillo TA, Roof KS, Crane CH, **Goodman KA**. Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848. *Int J Radiat Oncol Biol Phys*. 2024;118(1):107-114.
167. Verheij FS, Omer DM, Williams H, Lin ST, Qin LX, Buckley JT, Thompson HM, Yuval JB, Kim JK, Dunne RF, Marcet J, Cataldo P, Polite B, Herzig DO, Liska D, Oommen S, Friel

- CM, Ternent C, Coveler AL, Hunt S, Gregory A, Varma MG, Bello BL, Carmichael JC, Krauss J, Gleisner A, Guillem JG, Temple L, **Goodman KA**, Segal NH, Cercek A, Yaeger R, Nash GM, Widmar M, Wei IH, Pappou EP, Weiser MR, Paty PB, Smith JJ, Wu AJ, Gollub MJ, Saltz LB, Garcia-Aguilar J. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. *J Clin Oncol*. 2024;42(5):500-506.
168. Santoso AP, Vinogradskiy Y, Robin TP, **Goodman KA**, Schefter TE, Miften M, Jones BL. Clinical and Dosimetric Impact of 2D kV Motion Monitoring and Intervention in Liver Stereotactic Body Radiation Therapy. *Adv Radiat Oncol*. 2023 Nov 23;9(3):101409.
169. Hsieh K, Bloom JR, Jones BM, Hsieh C, Hassan A, Nehlsen AD, Salgado LR, **Goodman KA**, Green S, Rowley JP, Sindhu KK. Gender Representation Among Academic US Radiation Oncology Department Chairs: Who are They? *Adv Radiat Oncol*. 2024;9(5):101451.
170. Williams H, Thompson HM, Lin ST, Verheij FS, Omer DM, Qin LX, Garcia-Aguilar J; OPRA Consortium. Endoscopic Predictors of Residual Tumor After Total Neoadjuvant Therapy: A Post Hoc Analysis From the Organ Preservation in Rectal Adenocarcinoma Trial. *Dis Colon Rectum*. 2024 Mar 1;67(3):369-376.
171. Janczewski LM, Browner A, Cotler J, Nelson H, Ballman KV, LeBlanc M, Gollub MJ, Eng C, Brierley JD, Palefsky JM, Goldberg RM, **Goodman KA**, Washington MK, Asare EA, Palis B. Data-driven optimization of version 9 American Joint Committee on Cancer staging system for anal cancer. *Cancer*. 2024;130(9):1702-1710.
172. Dickstein DR, Edwards CR, Rowan CR, Avanesian B, Chubak BM, Wheldon CW, Simoes PK, Buckstein MH, Keefer LA, Safer JD, Sigel K, **Goodman KA**, Rosser BRS, Goldstone SE, Wong SY, Marshall DC. Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus. *Nat Rev Gastroenterol Hepatol*. 2024 Jun;21(6):377-405.
173. Janczewski LM, Asare EA, **Goodman KA**. Reply: Letter to the Editor of Annals Surgical Oncology Concerning "Updates on the Version 9 American Joint Committee on Cancer Staging System for Anal Cancer." Is the Anal Physical Examination Underestimated? *Ann Surg Oncol*. 2025 Feb;32(2):1134-1135.
174. Sanford NN, Narang AK, Aguilera TA, Bassetti MF, Chuong MD, Erickson BA, **Goodman KA**, Herman JM, Intven M, Kilcoyne A, Kim H, Paulson E, Reyngold M, Tsai S, Tchelebi LT, Tuli R, Versteijne E, Wei AC, Wo JY, Zhang Y, Hong TS, Hall WA. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy. *Int J Radiat Oncol Biol Phys*. 2025 Mar 15;121(4):918-929.
175. Williams H, Yuval JB, Verheij FS, Miranda J, Lin ST, Omer DM, Qin LX, Gollub MJ, Kim TH, Garcia-Aguilar J; **OPRA Consortium**. Baseline MRI predictors of successful organ preservation in the Organ Preservation in Rectal Adenocarcinoma (OPRA) trial. *Br J Surg*. 2024 Aug 30;111(9).

Karyn A. Goodman, MD, MS

176. Williams H, Omer DM, Thompson HM, Lin ST, Verheij FS, Miranda J, Yuval JB, Buckley J, Marco MR, Qin LX, Dombroski DA, Kedar R, Oto A, Korngold E, Veniero JC, Gandhi S, Krishnaraj A, Jagtiani M, Ohanian K, Vu D, Hope TA, Lee S, Wasnik AP, Madhuripan N, Gollub MJ, Garcia-Aguilar J; **OPRA Consortium**. MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer. *Radiology*. 2024 Sep;312(3):e232748.
177. Dickstein DR, Kapouranis T, Sigel K, Wheldon CW, Nvepu E, Javier NM, Stewart R, Galsky M, Sfakianos J, Safer JD, Stock R, **Goodman K**, Rosser BRS, Flynn KE, Marshall DC. Sexual Health Outcomes in Sexual Minority and Heterosexual Men After Prostate Radiation Therapy. *Int J Radiat Oncol Biol Phys*. 2025 Jun 1;122(2):416-423.
178. Cloyd JM, Sarna A, Arango MJ, Bates SE, Bhutani MS, Bloomston M, Chung V, Dotan E, Ferrone CR, Gambino PF, Goenka AH, **Goodman KA**, Hall WA, He J, Hogg ME, Jayaraman S, Kambadakone A, Katz MHG, Khorana AA, Ko AH, Koay EJ, Kooby DA, Krishna SG, Larsson LK, Lee RT, Maitra A, Massarweh NN, Mikhail S, Muzaffar M, O'Reilly EM, Palta M, Petzel MQB, Philip PA, Reingold M, Santa Mina D, Sohal DPS, Sundaresan TK, Tsai S, Turner KL, Vreeland TJ, Walston S, Washington MK, Williams TM, Wo JY, Snyder RA. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. *JAMA Surg*. 2025 Feb 1;160(2):172-180.

Other Peer Reviewed Publications including Reviews, Guidelines, and Editorials

1. **Goodman KA**, Thomas CR Jr. Making rational choices to improve neoadjuvant chemoradiation for rectal cancer. *Oncology* 2009; June; 22(7):830-831.
2. Dawood O, Mahadevan A, **Goodman KA**. Stereotactic Body Radiation Therapy for Liver Metastases. *Eur J Cancer*. 2009; 45(17):2947-59.
3. **Goodman KA**, Hajj C. Role of radiation therapy in the management of pancreatic cancer. *J Surg Oncol*. 2012 Jan; 107 (1): 86-96.
4. Høyer M, Swaminath A, Bydder S, Lock M, Méndez Romero A, Kavanagh B, **Goodman KA**, Okunieff P, Dawson LA. Radiotherapy for liver metastases: a review of evidence. *Int J Radiat Oncol Biol Phys*. 2012 Mar 1;82(3):1047-57.
5. Huguet F, **Goodman KA**, Azria D, Racadot S, Abrams RA. Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations. *Int J Radiat Oncol Biol Phys*. 2012 Aug 1;83(5):1355-64.
6. Jones WE 3rd, Thomas CR Jr, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW Jr, DAS P, **Goodman KA**, Hong TS, Jabbour SK, Konski AA, Koong AC, Rodriguez-Bigas M, Small W Jr, Zook J, Suh WW. ACR Appropriateness Criteria(R) Resectable Rectal Cancer. *Radiat Oncol*. 2012 Sep 24;7(1):161.
7. **Goodman KA**. Esophagogastric junction carcinoma: Introduction. *Semin Radiat Oncol*. 2013;23(1):1-2.
8. Wu AJ, **Goodman KA**. Positron emission tomography imaging for gastroesophageal junction tumors. *Semin Radiat Oncol*. 2013;23(1): 10-15.

9. Expert Panel on Radiation Oncology–Rectal/Anal Cancer, Hong TS, Pretz JL, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW, Das P, **Goodman KA**, Jabbour SK, Jones WE 3rd, Konski AA, Koong AC, Rodriguez-Bigas M, Small W Jr, Thomas CR Jr, Zook J, Suh WW. ACR Appropriateness Criteria®-Anal Cancer. *Gastrointest Cancer Res*. 2014 Jan;7(1):4-14.
10. **Goodman KA**, Milgrom SA, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW, Das P, Hong TS, Jabbour SK, Jones WE 3rd, Konski AA, Koong AC, Kumar R, Rodriguez-Bigas M, Small W Jr, Thomas CR Jr, Suh WW. ACR Appropriateness Criteria® Rectal Cancer: Metastatic Disease at Presentation. *Oncology (Williston Park)*. 2014 Oct 15;28(10).
11. **Goodman KA**. Refining the Role for Adjuvant Radiotherapy in Gastric Cancer: Risk Stratification Is Key. *J Clin Oncol*. 2015 Oct 1;33(28):3082-4.
12. Wu AJ, **Goodman KA**. Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet? *J Gastrointest Oncol*. 2015 Feb;6(1):53-9.
13. Yang TJ, **Goodman KA**. Predicting complete response: is there a role for non-operative management of rectal cancer? *J Gastrointest Oncol*. 2015 Apr;6(2):241-6.
14. Hajj C, **Goodman KA**. Role of Radiotherapy and Newer Techniques in the Treatment of GI Cancers. *J Clin Oncol*. 2015 Jun 1;33(16):1737-1744.
15. Hajj C, **Goodman KA**. Pancreatic cancer and SBRT: A new potential option? *Rep Pract Oncol Radiother*. 2015 Sep-Oct;20(5):377-84.
16. Daroui P, Jabbour SK, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW, Das P, **Goodman KA**, Hong TS, Jones WE 3rd, Kaur H, Konski AA, Koong AC, Kumar R, Pawlik TM, Small W Jr, Thomas CR Jr, Suh WW. ACR Appropriateness Criteria® Resectable Stomach Cancer. *Oncology (Williston Park)*. 2015 Aug;29(8):595-602.
17. Chargari C, Magne N, Guy JB, Rancoule C, Levy A, **Goodman KA**, Deutsch E. Optimize and refine therapeutic index in radiation therapy: Overview of a century. *Cancer Treat Rev*. 2016 Apr;45:58-67.
18. Julie DR, **Goodman KA**. Advances in the Management of Anal Cancer. *Curr Oncol Rep*. 2016 Mar;18(3):20.
19. Bridgewater JA, **Goodman KA**, Kalyan A, Mulcahy MF. Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling. *Am Soc Clin Oncol Educ Book*. 2016;35:e194-203.
20. Expert Panel on Radiation Oncology-Gastrointestinal, Small W Jr, Hayes JP, Suh WW, Abdel-Wahab M, Abrams RA, Azad N, Das P, Dragovic J, **Goodman KA**, Jabbour SK, Jones WE 3rd, Konski AA, Koong AC, Kumar R, Lee P, Pawlik TM, Herman JM. ACR Appropriateness Criteria® Borderline and Unresectable Pancreas Cancer. *Oncology (Williston Park)*. 2016 Jul;30(7):619-24, 627-632.

Karyn A. Goodman, MD, MS

21. **Goodman KA.** Stereotactic Body Radiation Therapy for Pancreatic Cancer. *Cancer J.* 2016 Jul-Aug;22(4):290-5.
22. **Goodman KA.** Timing Is Everything: What Is the Optimal Duration After Chemoradiation for Surgery for Rectal Cancer? *J Clin Oncol.* 2016 Nov 1;34(31):3724-3728.
23. **Goodman KA.** Definitive Chemoradiotherapy ("Watch-and-Wait" Approach). *Semin Radiat Oncol.* 2016 Jul;26(3):205-10.
24. Robin TP, **Goodman KA.** Radiation therapy in the management of pancreatic adenocarcinoma: review of current evidence and future opportunities. *Chin Clin Oncol* 2017;6(3):28.
25. Expert Panel on Radiation Oncology Gastrointestinal. Jones WE 3rd, Suh WW, Abdel-Wahab M, Abrams RA, Azad N, Das P, Dragovic J, **Goodman KA,** Jabbour SK, Konski AA, Koong AC, Kumar R, Lee P, Pawlik TM, Small W Jr, Herman JM; ACR Appropriateness Criteria® Resectable Pancreatic Cancer. *Am J Clin Oncol.* 2017 Apr;40(2):109-117.
26. **Goodman KA,** Kavanagh BD. Stereotactic Body Radiotherapy for Liver Metastases. *Semin Radiat Oncol.* 2017 Jul;27(3):240-246.
27. **Goodman KA.** Total neoadjuvant therapy for rectal cancer. *Cancer Radiother.* 2018 Sep;22(5):459-65.
28. Jain S, **Goodman KA.** Quality Control of Radiation Delivery for Lower Gastrointestinal Cancers. *Curr Treat Options Oncol.* 2018 Sep 7;19(10):51
29. Ladbury C, **Goodman K,** Schefter TE, Olsen JR. Anal Cancer in the Era of Dose Painted Intensity Modulated Radiation Therapy: Implications for Regional Nodal Therapy. *Semin Radiat Oncol.* 2019 Apr;29(2):137-143.
30. Hall WA, **Goodman KA.** Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. *Radiat Oncol.* 2019 Jun 26;14(1):114. doi: 10.1186/s13014-019-1277-1.
31. Lin D, Khan U, Goetze TO, Reizine N, **Goodman KA,** Shah MA, Catenacci DV, Al-Batran SE, Posey JA. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management? *Am Soc Clin Oncol Educ Book.* 2019 Jan;39:e88-e95.
32. Palta M, Godfrey D, **Goodman KA,** Hoffe S, Dawson LA, Dessert D, Hall WA, Herman JM, Khorana AA, Merchant N, Parekh A, Patton C, Pepek JM, Salama JK, Tuli R, Koong AC. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. *Pract Radiat Oncol.* 2019;9(5):322-332.
33. Russo S, Anker CJ, Abdel-Wahab M, Azad N, Das P, Dragovic J, **Goodman KA,** Herman JM, Jones W 3rd, Kennedy T, Konski A, Kumar R, Lee P, Patel NM, Sharma N, Small W, Suh WW, Jabbour SK; Expert Panel on Radiation Oncology- Local Excision in Rectal Cancer. Executive Summary of the American Radium Society Appropriate Use Criteria for Local Excision in Rectal Cancer. *Int J Radiat Oncol Biol Phys.* 2019;105(5):977-993.

34. Russo S, Anker CJ, Abdel-Wahab M, Azad N, Bianchi N, Das P, Dragovic J, **Goodman KA**, Jones W 3rd, Kennedy T, Kumar R, Lee P, Sharma N, Small W, Suh WW, Jabbour SK. Executive Summary of the American Radium Society Appropriate Use Criteria for Treatment of Anal Cancer. *Int J Radiat Oncol Biol Phys*. 2019;105(3):591-605.
35. Williams TM, Crane C, **Goodman K**. Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. *JAMA Surg*. 2020 Jan 2. doi: 10.1001/jamasurg.2019.5464.
36. Shah MA, Kennedy EB, Catenacci DV, Deighton DC, **Goodman KA**, Malhotra NK, Willett C, Stiles B, Sharma P, Tang L, Wijnhoven BPL, Hofstetter WL. Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. *J Clin Oncol*. 2020 Aug 10;38(23):2677-2694.
37. Scorsetti M, **Goodman KA**, Seong J, Loi M, Huguet F, Dawson LA. Hepatocellular Carcinoma in the COVID-19 Era: Primetime for Stereotactic Body Radiotherapy and a Lesson for the Future? *Oncologist*. 2020 Jun 11;25(8):e1249-50.
38. Tchelebi LT, Haustermans K, Scorsetti M, Hosni A, Huguet F, Hawkins MA, Dawson LA, **Goodman KA**. Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19. *Radiother Oncol*. 2020 Jul;148:194-200.
39. Ghiassi-Nejad Z, **Goodman K**. Non-surgical “Watch and Wait” Approach to Rectal Cancer. *Current Colorectal Cancer Reports*. 2020;16:118–124.
40. Anker CJ, Dragovic J, Herman JM, Bianchi NA, **Goodman KA**, Jones WE 3rd, Kennedy TJ, Kumar R, Lee P, Russo S, Sharma N, Small W, Suh WW, Tchelebi LT, Jabbour SK. Executive Summary of the American Radium Society Appropriate Use Criteria for Operable Esophageal and Gastroesophageal Junction Adenocarcinoma: Systematic Review and Guidelines. *Int J Radiat Oncol Biol Phys*. 2021 Jan 1;109(1):186-200.
41. Nehlsen AD, **Goodman KA**. Controversies in radiotherapy for pancreas cancer. *J Surg Oncol*. 2021;123(6):1460-1466
42. Horowitz DP, **Goodman K**, Kachnic LA. Ablative Radiotherapy for Patients With Inoperable Pancreas Cancer-Ready for Prime Time? *JAMA Oncol*. 2021;7(5):687-688.
43. Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, Dahia PLM, Fraker DL, **Goodman KA**, Hope TA, Kunz PL, Perez K, Perrier ND, Pryma DA, Ryder M, Sasson AR, Soulen MC, Jimenez C. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. *Pancreas*. 2021;50(4):469-493.
44. Lee SM, Wages NA, **Goodman KA**, Lockhart AC. Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician. *JCO Precis Oncol*. 2021;5:317-324.
45. Tchelebi LT, **Goodman KA**. Mature Experiences Using Local Therapy for Oligometastases. *Semin Radiat Oncol*. 2021 Jul;31(3):180-185.

Karyn A. Goodman, MD, MS

46. Nehlsen AD, **Goodman KA**. Controversies in radiotherapy for pancreas cancer. *J Surg Oncol*. 2021 May;123(6):1460-1466
47. Lee SM, Wages NA, **Goodman KA**, Lockhart AC. Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician. *JCO Precis Oncol*. 2021 Feb 1;5:317-324.
48. Hall WA, Dawson LA, Hong TS, Palta M, Herman JM, Evans DB, Tsai S, Ferrone CR, B Fleming J, Chang DT, Crane C, Koong AC, Oar A, Parikh P, Erickson B, Hoffe S, **Goodman KA**. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. *J Clin Oncol*. 2021 Dec 1;39(34):3773-3777.
49. Zwart WH, Hotca A, Hospers GAP, **Goodman KA**, Garcia-Aguilar J. The Multimodal Management of Locally Advanced Rectal Cancer: Making Sense of the New Data. *Am Soc Clin Oncol Educ Book*. 2022 Apr;42:1-14.
50. Eng C, Ciombor KK, Cho M, Dorth JA, Rajdev LN, Horowitz DP, Gollub MJ, Jácome AA, Lockney NA, Muldoon RL, Washington MK, O'Brian BA, Benny A, Lebeck Lee CM, Benson AB 3rd, **Goodman KA***, Morris VK*. Anal Cancer: Emerging Standards in a Rare Disease. *J Clin Oncol*. 2022 Aug 20;40(24):2774-2788.
51. Kumar R, Tchelebi L, Anker CJ, Sharma N, Bianchi NA, Dragovic J, **Goodman KA**, Herman JM, Jiang Y, Jones WE 3rd, Kennedy TJ, Lee P, Kundranda M, Russo S, Small W, Suh WW, Yee N, Jabbour SK. American Radium Society (ARS) Appropriate Use Criteria (AUC) for Locoregional Gastric Adenocarcinoma: Systematic Review and Guidelines. *Am J Clin Oncol*. 2022;45(9):391-402.
52. Jones BM, **Goodman KA**. BID It to Win It. *Int J Radiat Oncol Biol Phys*. 2022;114(5):831.
53. Shroff RT, **Goodman KA**, Mehnert JM, Vose JM, Moran SE, Yessaian JL, Baldo L, Alexander BM, Highsmith QB, Mills JM, Kunz PL. Where Are All the Women in Industry Advisory Boards? *J Clin Oncol*. 2022; Online ahead of print.
54. Hotca A, **Goodman KA**. Trends in Anal Cancer: Leveraging Public Health Efforts to Improve Cancer Care. *J Clin Oncol*. 2023; Online ahead of print.
55. Porter LD, **Goodman KA**, Mailman J, Garrett WS. Patient Advocates and Researchers as Partners in Cancer Research: A Winning Combination. *Am Soc Clin Oncol Educ Book*. 2023;43:e100035.
56. Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, **Goodman KA**, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL; NET CTPM participants. Consensus Report of the 2021 National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. *J Natl Cancer Inst*. 2023;115(9):1001-1010.
57. Snyder RA, Burtness B, Cho M, Del Rivero J, Doroshov DB, Hitchcock KE, Kalyan A, Kim CA, Lukovic J, Parikh AR, Sanford NN, Singh B, Shen C, Shroff RT, Vijayvergia N, **Goodman KA, Kunz PL**. *Shared Senior Authorship. The Room Where It Happens:

Addressing Diversity, Equity, and Inclusion in NCTN Clinical Trial Leadership. *J Natl Cancer Inst.* 2023;115(10):1132-1138.

58. Iheagwara UK, Patel S, Diaz DA, Yom SS, **Goodman KA**, Barry PN. Promoting Women and Historically Excluded Minorities in Medicine as Essential Leaders of Research. *Adv Radiat Oncol.* 2023;8(6):101301.
59. Kennecke HF, Auer R, Cho M, Dasari NA, Davies-Venn C, Eng C, Dorth J, Garcia-Aguilar J, George M, **Goodman KA**, Kreppel L, Meyer JE, Monzon J, Saltz L, Schrag D, Smith JJ, Zell JA, Das P; NCI Rectal-Anal Task Force. NCI Rectal-Anal Task Force Consensus Recommendations for Design of Clinical Trials in Rectal Cancer. *J Natl Cancer Inst.* 2023;115(12):1457-1464.
60. Worrell SG, **Goodman KA**, Altorki NK, Ashman JB, Crabtree TD, Dorth J, Firestone S, Harpole DH, Hofstetter WL, Hong TS, Kissoon K, Ku GY, Molena D, Tepper JE, Watson TJ, Williams T, Willett C. The Society of Thoracic Surgeons/American Society for Radiation Oncology Updated Clinical Practice Guidelines on Multimodality Therapy for Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction. *Ann Thorac Surg.* 2024;117(1):15-32.
61. **Goodman KA**, Hotca A, Liu M, Strong VE, Ilson DH. Top advances of the year: Gastroesophageal cancer. *Cancer.* 2024;130(13):2253-2256.
62. Janczewski LM, Asare EA, **Goodman KA**. Updates on the Version 9 American Joint Committee on Cancer Staging System for Anal Cancer. *Ann Surg Oncol.* 2024;31(7):4155-4158.
63. Liu J, Sidiqi B, McComas K, Gogineni E, Andraos T, Crane CH, Chang DT, **Goodman KA**, Hall WA, Hoffe S, Mahadevan A, Narang AK, Lee P, Williams TM, Chuong MD. SBRT for Pancreatic Cancer: A Radiosurgery Society Case-Based Practical Guidelines to Challenging Cases. *Pract Radiat Oncol.* 2024. Nov-Dec;14(6):555-573.
64. Feng M, Hallemeier CL, Almada C, Aranha O, Dorth J, Felder S, **Goodman KA**, Holliday EB, Jethwa KR, Kachnic LA, Miller ED, Murphy JD, Pollom E, Sio TT, Thomas H, Lindsay P, Bradfield L, Helms AR, Czito BG. Radiation Therapy for Anal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline. *Pract Radiat Oncol.* 2025. Online ahead of print.
65. Lehrer EJ, Khunsriraksakul C, Garrett S, Trifiletti DM, Sheehan JP, Guckenberger M, Louie AV, Siva S, Ost P, **Goodman KA**, Dawson LA, Tchelebi LT, Yang JT, Showalter TN, Park HS, Spratt DE, Kishan AU, Gupta GP, Shah C, Fanti S, Calais J, Wang M, Schmitz K, Liu D, Abraham JA, Dess RT, Buvat I, Solomon B, Zaorsky NG. Future directions in the evaluation and management of newly diagnosed metastatic cancer. *Crit Rev Oncol Hematol.* 2025;208:104631.
66. Jabbour SK, Higgins KA, Yom SS, **Goodman KA**. Recapping Radiation Related Abstracts at ASCO 2024: A Commentary about the Fundamental Role of Radiation Therapy in Esophageal and Lung Cancers. *Int J Radiat Oncol Biol Phys.* 2024;120(2):309-314.
67. Rajdev L, King GG, Lieu CH, Cohen SA, Pant S, Uboha NV, Deming D, Malla M, Kasi A, Klute K, Spencer KR, Dasari A, Morris VK, Botta G, Lowy AM, O'Hara MH, Eads J, King D,

Shah MA, Hong TS, Parikh A, Klempner SJ, Jabbour SK, Chawla A, Molena D, George TJ, Gibson MK, Allegra C, **Goodman K**, Eng C, Philip PA. Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group. *JCO Precis Oncol*. 2025 Mar;9:e2400489.

Book Chapters

1. Zelefsky MJ, Valicenti RK, **Goodman KA**, Perez CA. Prostate Cancer (Chapter 58). In: Principles and Practice of Radiation Oncology, 4th Edition. Perez CA, Brady LW, Halperin EC, Schmidt-Ullrich RK, editors. Baltimore, MD: Lippincott, Williams & Wilkins; 2004, pp. 1692-1762.
2. **Goodman KA**, Koong AC. CyberKnife Radiosurgery for Pancreatic Cancer (Chapter 25). In: Pioneering Techniques in Robotic Radiosurgery, Vol. 1; 2005, and pp. 275-287.
3. **Goodman KA**. Stereotactic Radiosurgery for Pancreatic Cancer (Chapter 22). In: Treating Tumors that Move with Respiration. Urschel HC, Kresl JJ, Luketich JD, Papiez L, Timmerman RD, editors. New York, NY: Springer; 2007, pp 217-226.
4. Soltys SG, **Goodman KA**, Koong AC. CyberKnife Radiosurgery for Pancreatic Cancer (Chapter 23). In: Treating Tumors that Move with Respiration. Urschel HC, Kresl JJ, Luketich JD, Papiez L, Timmerman RD, editors. New York, NY: Springer; 2007, pp 227-240.
5. Wu AJ, **Goodman KA**. Malignant – Lymphoma (Chapter 57). In: Esophageal Tumors: Principles and Practice. Jobe B, Thomas C, Hunter J, editors. New York, NY: Demos Medical Publishing; 2009, pp. 836-846.
6. Minsky BD, **Goodman KA**, Warren B. Cancer of the Esophagus (Chapter 37). In: Leibel and Phillips Textbook of Radiation Oncology, 3rd Edition. Hoppe R, Phillips T, Roach M, editors. Philadelphia, PA: Elsevier Saunders; 2010, pp.772-787.
7. **Goodman KA**, Wagman R, Ho A. Cancer of the Liver, Gallbladder and Bile Duct (Chapter 39). In: Leibel and Phillips Textbook of Radiation Oncology, 3rd Edition. Hoppe R, Phillips T, Roach M, editors. Philadelphia, PA: Elsevier Saunders; 2010, pp. 820-841.
8. **Goodman KA**, Das Gupta T, Kachnic LA. Intensity Modulated Radiotherapy for Anal Cancer. In: Lower Gastrointestinal Malignancies. Radiation Medicine Rounds. Koong A, Ben-Josef E, editors. 2012
9. Reidy-Lagunes D, **Goodman KA**, Saltz LB. Unusual Tumors of the Colon, Rectum, and Anus (Chapter 34). In: Textbook of Uncommon Cancer, Fourth Edition. Raghavan D, Blanke CD, Johnson DH, Moots PL, Reaman GH, Rose PG and Sekeres MA, editors. John Wiley & Sons, Inc; 2012.

Karyn A. Goodman, MD, MS

10. Wu AJ, **Goodman KA**. Oesophagus: Principles of radiation and chemotherapy for oesophageal cancer (Chapter 91). In: European Society of Thoracic Surgery Textbook of Thoracic Surgery. Kuzdzal J, editor. Medycyna Praktyczna, Krakow; 2014.
11. **Goodman KA**, Czito B, Kachnic LA. Cancer of the Anal Canal (Chapter 79). In: Abeloff's Clinical Oncology, 5th Edition. Niederhuber, Armitage, Doroshow, Kastan, Tepper, editors. Elsevier, Philadelphia, PA; 2014, pp. 1360 – 1372.
12. Hajj C, **Goodman KA**. Radiation Treatment for Gastric Cancer (Chapter 23). In: Gastric Cancer: Principles and Practice. Strong V. editor. Springer International Publishing, Switzerland; 2015, pp. 307-315.
13. Welton MA, Gunderson LL, **Goodman KA** et al. Anal Cancer. In: AJCC Cancer Staging Manual. 8th Ed. Amin, M.B., Edge, S.B., Greene, F.L., et al. editors. New York: Springer; 2017.
14. **Goodman KA**, Amini A. Stereotactic Body Radiation Therapy for Liver Metastases: Background and Clinical Evidence (Chapter 17). In: Radiation Therapy for Gastrointestinal Cancers. Hong T, Das P, editors. Springer, Cham, Switzerland; 2017, pp 217-228.
15. **Goodman KA**, Amini A. Stereotactic Body Radiation Therapy for Liver Metastases: Radiation Therapy Planning (Chapter 18). In: Radiation Therapy for Gastrointestinal Cancers. Hong T, Das P, editors. Springer, Cham, Switzerland; 2017, pp 229-238.
16. Westerly DC, **Goodman KA**. External Beam Radiation Therapy for Liver Tumors: Simulation, Treatment Planning, and Advanced Delivery Techniques. In: Radiation Therapy for Liver Tumors: Fundamentals and Clinical Practice. Meyer J, Schefter TE, editors. Springer, Cham, Switzerland; 2017, pp 91-105.
17. Lanning RM and **Goodman KA**. Radiation Therapy: The North American Approach (Chapter 21). In: Comprehensive Rectal Cancer Care, M. Kwaan, A. Zbar, editors. Springer Nature, Cham, Switzerland 2019, pp 365-403.
18. Posner MC, **Goodman KA**, Ilson DH. Cancer of the Esophagus. (Chapter 52). In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 11th edition. Devita VT, Lawrence TS, Rosenberg SA, editors. Philadelphia, PA: Wolters Kluwer 2019.
19. **Goodman KA**, Posner MC, Ilson DH. Cancer of the Esophagus. (Chapter 33). In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 12th edition. Devita VT, Lawrence TS, Rosenberg SA, editors. Philadelphia, PA: Wolters Kluwer 2023.
20. **Goodman KA**, Gollub M, Eng C, et al. Anus. In: AJCC Staging Protocol Version 9. American Joint Committee on Cancer/American College of Surgeons; 2023.

INVITED LECTURES/PRESENTATIONS

Refresher Courses

1. Radiology Society of North America (RSNA) 2008 Refresher Course RO41 - BOOST: Gastrointestinal - Anatomy, Natural History, and Contouring, Chicago, IL, 12/3/08

2. American Society of Therapeutic Radiology and Oncology (ASTRO) 2009 E-contouring Course: Gastrointestinal Cancers, Chicago, IL, 11/1/09
3. Radiology Society of North America (RSNA) 2008 Refresher Course RO41 - BOOST: Gastrointestinal - Anatomy, Natural History, and Contouring, Chicago, IL, 12/2/09
4. American Society of Therapeutic Radiology and Oncology (ASTRO) 2010 E-contouring Course: Gastrointestinal Cancers, San Diego, CA, 10/30/10
5. American Society of Therapeutic Radiology and Oncology (ASTRO) 2011 E-contouring Course: Gastrointestinal Cancers, Miami, FL, 10/1/11
6. American Society of Therapeutic Radiology and Oncology (ASTRO) 2011 Educational Session: Cancer of the Colon, Rectum and Anus, Miami, FL, 10/3/10
7. Radiology Society of North America (RSNA) 2011 Refresher Course RO41 - BOOST: Gastrointestinal - Anatomy, Natural History, and Contouring, Chicago, IL, 11/29/11
8. American Society of Clinical Oncology (ASCO) 2012 Annual Meeting Education Session: Rectal Cancer: New Paradigms beyond Standard Chemotherapy and Radiation, Chicago, IL, 6/3/12
9. American Society of Therapeutic Radiology and Oncology (ASTRO) 2012 E-contouring Course: Gastrointestinal Cancers, Boston, MA, 10/28/12
10. American Society of Therapeutic Radiology and Oncology (ASTRO) 2012 Educational Session: Cancer of the Colon, Rectum and Anus, Boston, MA, 10/29/12
11. Radiology Society of North America (RSNA) 2012 Refresher Course RO41 - BOOST: Gastrointestinal - Anatomy, Natural History, and Contouring, Chicago, IL, 11/26/12
12. American Society of Therapeutic Radiology and Oncology (ASTRO) 2013 E-contouring Course: Gastrointestinal Cancers, Atlanta, GA, 9/22/13
13. American Society of Therapeutic Radiology and Oncology (ASTRO) 2013 Educational Session: Cancer of the Colon, Rectum and Anus, Atlanta, GA, 9/24/13
14. American Society of Therapeutic Radiology and Oncology (ASTRO) 2015 Refresher Course: Gastrointestinal Cancers, New Orleans, LA, 3/7/15
15. American Society of Therapeutic Radiology and Oncology (ASTRO) 2016 Refresher Course: Gastrointestinal Cancers, La Jolla, CA 3/12/16
16. American Society of Therapeutic Radiology and Oncology (ASTRO) 2016 Educational Session: Cancer of the Colon, Rectum and Anus, Boston, MA, 9/26/16
17. American Society of Therapeutic Radiology and Oncology (ASTRO) 2017 Educational Session: Cancer of the Colon, Rectum and Anus, San Diego, CA, 9/25/17

Karyn A. Goodman, MD, MS

18. American Society of Therapeutic Radiology and Oncology (ASTRO) 2018 Educational Session: Cancer of the Colon, Rectum and Anus, San Antonio, TX, 10/22/18
19. American Society of Therapeutic Radiology and Oncology (ASTRO) 2018 Educational Session: Clinical Trials Design and Methodology Education in Radiation Oncology, San Antonio, TX, 10/23/18

Invited Lectures

United States:

1. UCSF Radiation Oncology Grand Rounds, "New Radiotherapy Approaches to Pancreatic and Hepatobiliary Cancers". San Francisco, CA 3/24/05
2. MSKCC Radiation Oncology Grand Rounds, "Image-guided radiotherapy for gastrointestinal malignancies." 12/21/05
3. American Association of Physicists in Medicine Southern California Chapter Midwinter Symposium: Medical Physics at the Dawn of the 21st Century: New Devices and Strategies. "Robotic Radiosurgery for Pancreatic Cancer and Liver Malignancies." Burbank, CA, 1/19/07
4. Cleveland Clinic First International Symposium on Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery. "Stanford data on stereotactic body radiosurgery for liver and pancreas tumors." Orlando, FL, 2/23/07
5. MSKCC Surgery Grand Rounds, "Image-guided radiotherapy for gastrointestinal malignancies." 10/22/07
6. New York Cancer Society Panel Discussion. "Advances in Treatment Planning and Delivery of Radiotherapy for Gastric Cancer." New York, NY, 11/14/07
7. MSKCC Radiation Oncology Grand Rounds, "Advances in pelvic radiotherapy: defining the target volume." 1/16/08
8. Physician Education Resource Upper GI Malignancies Symposium, "Radiation therapy for Esophageal Cancer." Philadelphia, PA, 9/6/08
9. Northern New England Clinical Oncology Society Annual Meeting, "Advances in Radiotherapy for Rectal Cancer." Whitefield, NH, 10/18/08
10. New York Roentgen Society Meeting, "IMRT for Gastrointestinal Cancers." New York, NY, 10/22/08
11. MSKCC Alumni Society Annual Meeting, "What is the role of radiation in local recurrence of rectal cancer?" New York, NY 11/20/08

Karyn A. Goodman, MD, MS

12. Cleveland Clinic Third Annual International Symposium on Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery, "Image-guided Radiotherapy for Pancreas and Liver Malignancies." Orlando, FL, 2/22/09
13. Eighth International Congress on Gastrointestinal Malignancies, "Current Concepts in Radiation Therapy for Esophageal Cancer", Washington, DC. 10/29/09
14. American Society of Therapeutic Radiology and Oncology (ASTRO) 2009 Annual Meeting, "Management of primary liver malignancy and liver metastasis." Chicago, IL, 11/1/09
15. MSKCC Pancreatic Cancer Symposium, "Radiotherapy: where does it fit?" New York, NY, 10/02/10
16. New York Roentgen Society Annual Meeting, 2010, "Adjuvant Management of Pancreatic Carcinoma." New York, NY, 10/14/10
17. American Society of Therapeutic Radiology and Oncology (ASTRO) 2010 Annual Meeting, "Discussion of Oral Abstracts on Upper Gastrointestinal Cancers", San Diego, CA, 11/2/10
18. MSKCC Alumni Society Annual Meeting, "Issues with planning radiotherapy for esophageal and gastric cancers" New York, NY, 11/18/10
19. MSKCC Radiation Oncology Grand Rounds, "Management of Pancreatic Cancer: Are We Entering a New Era?" and "Directing Therapy for Gastrointestinal Cancers: The emerging role of imaging as a biomarker and guide for radiotherapy" New York, NY 1/12/11
20. ASCO 2011 Gastrointestinal Cancer Symposium Educational Session, "Chemoradiation and the Role of Intensity-modulated Radiotherapy (IMRT) in Pancreatic Cancer", San Francisco, CA, 1/21/11
21. Cleveland Clinic International Symposium on Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery. "Stereotactic body radiosurgery for liver and pancreas tumors." Orlando, FL, 2/27/11
22. American Society of Therapeutic Radiology and Oncology (ASTRO) 2011 State of the Art Techniques: IMRT, IGRT and SBRT Symposium, "Upper Abdomen IMRT/IGRT/Anatomy." Las Vegas, NV, 3/13/11
23. Visiting Professor, Stanford University Department of Radiation Oncology. "Directing Therapy for Esophageal Cancer: The emerging role of imaging as a biomarker and guide for RT delivery." Stanford, CA, 7/6/2011
24. American Society of Therapeutic Radiology and Oncology (ASTRO) 2011 Annual Meeting, Plenary Session Discussant "ACCORD12/0405-ProDIGE 2 Trial of Neoadjuvant Treatment in Rectal Cancer: On Beyond Oxaliplatin", Miami, FL 10/3/11
25. MSKCC Alumni Society Annual Meeting, "The Role of IMRT in Anal Cancer: Is It the New Standard?" 11/17/11

Karyn A. Goodman, MD, MS

26. ASCO 2012 Gastrointestinal Cancer Symposium, "Role of PET in Staging and Treatment of Gastric and Esophageal Cancers", San Francisco, CA, 1/19/12
27. Cleveland Clinic International Symposium on Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery. "DEBATE: Radio Frequency Ablation vs. SBRT for Liver Metastases." Orlando, FL, 2/25/12
28. Cleveland Clinic Department of Radiation Oncology Grand Rounds. "Management of Pancreatic Cancer: Are We Entering a New Era?" Cleveland, OH, 4/20/12.
29. American Society of Therapeutic Radiology and Oncology (ASTRO) 2012 Symposium on State of the Art Techniques: IMRT, IGRT and SBRT, Protons and Brachytherapy, "Upper Abdomen Anatomy" and "Anal Cancer: IMRT / Rectal Cancer: IMRT vs. CRT." Las Vegas, NV, 5/5/12-5/6/12
30. MSKCC Interventional Radiology Grand Rounds Lecture, "Management of Pancreatic Cancer", New York, NY, 6/25/12
31. MSKCC Radiation Oncology Grand Rounds, "Emerging Radiotherapeutic Options for Primary and Metastatic Liver Tumors" New York, NY, 12/5/12
32. American Society of Therapeutic Radiology and Oncology (ASTRO) 2013 Symposium on State of the Art Techniques: IMRT, IGRT and SBRT, Protons and Brachytherapy, "Upper Abdomen Anatomy" and "Stereotactic body radiosurgery for liver, adrenal, and retroperitoneal tumor." San Antonio, TX, 5/18/13
33. University of Pennsylvania 2nd Annual Course on Clinical Trials in Radiation Oncology, "Examining Imaging in Radiotherapy Trials." Philadelphia, PA, 10/4/13
34. Visiting Professor, Fox Chase Cancer Center. "Stereotactic body radiosurgery for liver and pancreas tumors." Philadelphia, PA, 11/7/13
35. Philadelphia Roentgen Ray Society. "New Paradigms for the Management of Rectal Cancer", Philadelphia, PA, 11/7/13
36. MSKCC Radiation Oncology Grand Rounds, "Radiotherapy for Esophageal and Pancreas Cancers: Rationale and Emerging Therapeutic Options", New York, NY, 11/13/13
37. Los Angeles Radiology Society Annual Meeting. "Directing Therapy for Esophageal Cancer: The Emerging Role of Imaging as a Biomarker and Guide for RT Delivery." Pasadena, CA, 2/24/14
38. Practical Brachytherapy in Oncology Symposium. "Advanced in Endoluminal Esophageal Brachytherapy." New York, NY, 5/22/14
39. American Association of Physicists in Medicine Summer School. "Stereotactic body radiosurgery for liver and pancreas tumors." Burlington, VT, 6/24/14

Karyn A. Goodman, MD, MS

40. University of Colorado Visiting Professor Lecture, "Stereotactic body radiotherapy for pancreas cancer." Aurora, CO 10/11/14
41. MSKCC Alumni Society Annual Meeting, "Stereotactic Body Radiotherapy for Locally Advanced Pancreas Cancer" 10/16/14
42. New York Roentgen Society Annual Meeting, "Management of Liver Metastases." New York, NY, 10/23/14
43. Grand Rapids CCOP Distinguished Speaker Lecture, "Advances in Radiation Oncology Treatment." Grand Rapids, MI, 11/14/14
44. David Rubenstein Center for Pancreatic Research Meeting, "The evolving role of radiotherapy in pancreatic cancer: Incorporating advances in technology and radiobiology to hit the target" 12/18/14
45. ASCO Gastrointestinal Cancers Symposium, "Multidisciplinary Case Review of Stage IV Colon and Rectal cancers." San Francisco, CA, 1/15/15
46. Cleveland Clinic International Symposium on Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery, "Liver SBRT: Clinical Outcomes and Practical Considerations." Orlando, FL, 2/21/15
47. Johns Hopkins Visiting Professor Lecture, "Individualizing Therapy for Primary Rectal Tumors and Colorectal Liver Metastases." Baltimore, MD, 4/3/15
48. University of Pennsylvania Clinical Trials in Oncology Course and Workshop, "Examining Imaging in Clinical Trials." Philadelphia, PA, 4/17/15
49. National Pancreas Foundation Fellows Symposium, "Radiotherapy for Pancreatic Cancer: Where does it fit?" Baltimore, MD, 4/25/15
50. American College of Radiation Oncology 21st Annual kukuna-o-ka-la Radiation Oncology Conference, "SBRT for abdominal malignancies: Practical Considerations" "SBRT for Pancreas Cancer" "SBRT for Liver Tumors", Maui, Hawaii, 1/26-28/16
51. Oregon Health Sciences University Visiting Professor Lecture and 8th Annual WECAN Esophageal Cancer Research Forum, "Directing Therapy for Esophageal Cancer:
52. The Emerging Role of Imaging as a Biomarker and Guide for RT Delivery." Portland, OR, 3/5/16
53. University of Texas Southwestern Visiting Professor Lecture, "Individualizing Radiotherapy for Colorectal Cancer." Dallas, TX, 4/22/16
54. American Society of Clinical Oncology Annual Meeting, "Adjuvant and Definitive Therapy Options for Biliary Tract Cancer." Chicago, IL, 6/4/16
55. University of Pennsylvania Clinical Trials in Oncology Course and Workshop, "Examining Imaging in Oncology Trials." Philadelphia, PA, 10/21/16

Karyn A. Goodman, MD, MS

56. Mayo Clinic Pancreatic Cancer Conference, "Radiation Techniques." Scottsdale, AZ, 11/18/16
57. ASCO Gastrointestinal Cancers Symposium, "Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer." San Francisco, CA, 1/19/17
58. Moffitt Cancer Center Visiting Professor Lecture, "Pancreas and Liver Stereotactic Body Radiotherapy." Tampa, FL, 4/25/17
59. American Roentgen Society 99th Annual Meeting, "Presidential Course on Clinical Trials in GI Malignancies." Colorado Springs, CO, 5/6/17
60. Cedars Sinai Medical Center Visiting Professor Lecture, "Non-operative Management for Rectal Cancer." Los Angeles, CA, 6/23/17
61. ASCO/AACR Methods in Clinical Cancer Research Workshop Lecture, "Combination and Multimodality Trials: Many Variables but One Question." Vail, CO, 8/1/17
62. International Society of Gastrointestinal Oncology Annual Meeting, "PET scans for Directing Therapy in Esophageal Cancer." Arlington, CA, 10/26/17
63. Mayo Clinic Arizona Visiting Professor Lecture, "Technological Advances in the Management of Esophageal Cancer: Improving the Therapeutic Ratio." Scottsdale, AZ, 11/30/17
64. Emory University Visiting Professor and Winship Cancer Institute Grand Rounds Lecture, "Individualizing the Management of Rectal Cancer: Is There a Role for Non-Operative Management?" Atlanta, GA, 4/11/18
65. ASCO/AACR Methods in Clinical Cancer Research Workshop Lecture, "Combination and Multimodality Trials: Many Variables but One Question." Vail, CO, 7/29/18
66. University of Kansas Visiting Professor Grand Rounds Lecture, "Liver SBRT: Why, When, How?" Kansas City, KS, 9/12/18
67. Saccomanno Lecture and Western Colorado Cancer Day Lecture, "Improvements in targeting cancer using novel radiotherapy techniques, immunotherapy, personalized medicine, clinical trials and more." Grand Junction, CO, 10/12 – 10/13/19
68. MSKCC Alumni Society Annual Meeting, "Tailoring Neoadjuvant Therapy to Tumor Biology in Esophagogastric Cancer." New York, NY, 10/18/19
69. ASCO 2019 Gastrointestinal Cancers Symposium, "Biomarkers for Individualized Management and Response Assessment." San Francisco, CA, 1/17/19
70. Cleveland Clinic 12th Annual International Symposium on Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery, "Pancreas SBRT: When, Why, How." Orlando, FL, 2/24/19

71. Thomas Jefferson University, Visiting Professor Grand Rounds Lecture, "Stereotactic Body Radiotherapy for Liver Tumors: Why, When, How?", Philadelphia, PA, 4/25/19
72. ASCO/AACR Methods in Clinical Cancer Research Workshop Lecture, "Multimodality Trials: Many Variables but One Question." Vail, CO, 7/28/19
73. American Society of Therapeutic Radiology and Oncology (ASTRO) 2019 Annual Meeting, Presidential Symposium, "The Role of Local Therapies in the Management of Patients with Metastatic Disease." Chicago, IL 9/15/19
74. American Society of Therapeutic Radiology and Oncology (ASTRO) 2019 Annual Meeting," Real-Time Imaging-Based Biomarkers to Guide Personalized Radiotherapy for Gastrointestinal Malignancies: Esophageal Cancer." Chicago, IL 9/18/19
75. Radiological Society of North America (RSNA) 2019 Annual Meeting, "Rad Onc: Is XRT a Good Alternative to Ablation? Any Data Specifically for CLM?" Chicago, IL, 12/3/19
76. American College of Radiation Oncology (ACRO) 2020 Annual Meeting, "Total neoadjuvant therapy (TNT) and non-operative management (NOM) for rectal cancer: Are they ready for prime time?" Fort Lauderdale, FL, 2/29/20
77. American Society of Clinical Oncology (ASCO) 2020 Annual Meeting, "Feeling the Burn: Exposing Disparities in Radiation Oncology as a Benchmark for Change" Virtual Meeting, 05/29/22
78. American Association of Cancer Research (AACR) 2020 Annual Meeting, "Design of Multimodality Clinical Trials" Virtual Meeting, 06/22/20-06/24/20
79. New York Roentgen Society 2020 Annual Meeting, "SBRT for GI Cancers." Virtual Meeting, 10/30/20
80. American Society of Therapeutic Radiology and Oncology (ASTRO) 2021 Annual Meeting. "SBRT for Pancreas Cancer" Chicago, IL, 10/22/21
81. University of Miami Department of Radiation Oncology Virtual Visiting Professor Grand Rounds Lecture, "Management of Locally Advanced Esophageal Cancer: Improving the Therapeutic Ratio," 11/11/21
82. Rutgers University, Cancer Institute of New Jersey, Department of Radiation Oncology Grand Rounds Lecture, "Management of Locally Advanced Esophageal Cancer: Improving the Therapeutic Ratio," 12/7/21
83. Northwell Health Best of Radiation Oncology 2022 Virtual Conference, "Updates in GI Tumors" 11/14/22
84. 2022 ASCO Gastrointestinal Cancers Symposium, "Preoperative Chemoradiation Versus Perioperative Chemotherapy for Lower Esophageal and Gastroesophageal Junction Adenocarcinoma," San Francisco, CA 1/20/22

Karyn A. Goodman, MD, MS

85. 7th Annual School of Gastrointestinal Oncology (SOGO), "Locoregional GI Cancer Management" Washington, DC, 3/26/22
86. American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, "Radiation Therapy for Rectal Cancer: How to Choose?" Chicago, IL, 06/5/22
87. Great Debates & Updates in Gastrointestinal Malignancies, "Short-Course vs. Long-Course Neoadjuvant Radiation Therapy in Rectal Cancer" and "Is there a Role for Radiation Therapy in Borderline Resectable Pancreatic Cancer?" Virtual Meeting, 8/10-8/11/22
88. Massachusetts General Hospital (MGH) Department of Radiation Oncology Grand Rounds Lecture, "Navigating the NCTN: Ensuring workforce equity and diversity improves the quality of our national clinical trials." Boston, MA, 12/9/22
89. MSK CME 2023 Imaging of Alimentary Tract Cancers: Challenges and Opportunities in the Multidisciplinary Management of GI Cancers, "Anal Cancer Treatment Planning - The Role of Imaging From Diagnosis to Discharge." New York, NY, 5/9/23
90. MSKCC's 7th Annual Advances in Colorectal Oncology, "Update from RAPIDO Trial Discussant." New York, NY, 11/10/2023
91. 2024 ASCO Gastrointestinal Cancers Symposium, "Controversies in Neoadjuvant Management of Esophageal Cancer and Gastroesophageal Cancers: The Benefits and Risks of CROSS and PET-Directed Therapy," San Francisco, CA, 1/18/2024
92. University of Arizona Cancer Center Invited Grand Rounds Speaker, "Incorporating the Latest Data into Practice for Patients with Locally Advanced Rectal Cancer," Tucson, AZ, 2/16/2024
93. Duke University Department of Radiation Oncology Grand Rounds Lecture, "Incorporating the Latest Data into Practice for Patients with Locally Advanced Rectal Cancer," Durham, NC, 4/11/2024
94. 2024 Biennial International Society of Radiosurgery (ISRS) Congress, "Rationale for Hypofractionation in SBRT," New York, NY, 5/15/2024
95. American Society of Clinical Oncology (ASCO) 2024 Annual Meeting Plenary Session, "Discussion of the ESOPEC Trial. Beyond FLOT v. CROSS: Moving Toward More Tailored Therapy for Esophageal and GEJ Adenocarcinomas," Chicago, IL, 6/2/2024
96. American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, "NRG Oncology/RTOG 0848 Trial: Adjuvant Chemotherapy +/- Chemoradiation For Patients With Resected Head of Pancreas Adenocarcinoma - Results of the RT + 5FU/Capecitabine Randomization Step," Chicago, IL, 6/4/2024.
97. Maimonides Hospital Department of Radiation Oncology Grand Rounds, "Incorporating the Latest Data into Practice for Patients with Locally Advanced Rectal Cancer," Brooklyn, NY, 6/21/2024

Karyn A. Goodman, MD, MS

98. First Annual NYC Pancreatic Cancer Consortium, "RTOG 0848: Role of adjuvant RT," New York, NY, 11/14/2024
99. Emerging Science Webinar Series, HPV Cancers Alliance, Anal Cancer Experts Panel, New York, NY, 11/20/24
100. University of Florida (UF) Health Cancer Center Oncology Grand Rounds, "Moving Toward More Tailored Therapy for Esophageal and Gastroesophageal Junction Adenocarcinomas," Gainesville, FL, 12/11/2024
101. Northwell Health 10th Annual Best of Radiation Oncology, "Updates in GI Malignancies," New York, NY, 2/7/2025
102. Cleveland Clinic 17th Annual International Symposium on Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery, "Pancreas SBRT: When, Why, How." Orlando, FL, 2/23/25
103. Yale Department of Radiation Oncology Grand Rounds and Yale Center for GI Cancers Seminar Series, " Navigating the NCI's National Clinical Trials Network: The Hitchhiker's Guide to Opening NCTN Trials," and "Moving Toward More Tailored Therapy for Esophageal and Gastroesophageal Junction Adenocarcinomas," New Haven, CT, 4/17/2025
104. MD Anderson Cancer Center Department of Radiation Oncology Grand Rounds, "Navigating the NCTN: A Tale of Two Trials," Houston, TX, 5/8/2025

Abroad:

1. 3rd Acta Oncologica Symposium on Stereotactic Body Radiotherapy, "4D Metabolic and Anatomic Imaging in the Planning and Delivery of Radiotherapy for GI Malignancies". Copenhagen, Denmark, 6/15/06
2. Sino-American Colorectal Conference, "Image-guided Radiotherapy for Lower Gastrointestinal Malignancies." Fudan University, Shanghai, China, 10/24/09
3. Open Medical Institute of the American Austrian Foundation, "Gastrointestinal Oncology Seminar." Salzburg, Austria, 2/13/11 – 2/19/11
4. Second Sino-American Colorectal Conference, "Neoadjuvant chemoradiotherapy for locally advanced rectal cancer." Fudan University, Shanghai, China, 10/9/11
5. First Carioca Gastrointestinal Tumor Symposium, "Directing Therapy for Esophageal Cancer" and "New Paradigms for the Management of Rectal Cancer." Rio de Janeiro, Brazil, 11/9-11/10/12
6. CANCER CI –2013, "SBRT for Liver Cancer" and "Chemo-RT in Esophageal Cancer – Neoadjuvant vs Adjuvant", Hyderabad, India, 2/8 – 2/9/13
7. The OESO 12th World Conference, "Chemo-Radiotherapy – Future directions – Towards personalized medicine", Paris, France, 8/30/13

8. III International Congress of Gastrointestinal Cancer- Hospital Sirio Libanese/ MSKCC , “Role of Radiotherapy for Pancreatic Adenocarcinoma” and “New Paradigms for Rectal Cancer”, São Paulo, Brazil, 9/6- 9/7/13.
9. Visiting Professor, Prince of Wales Hospital and Queen Mary Hospital, Hong Kong, China, 3/24 – 3/26/2014
10. Fudan University Shanghai Cancer Center International Colorectal Cancer Symposium, “Individualizing Treatment for Colorectal Cancer: A Radiation Oncologist’s View.” Shanghai, China 11/14/15
11. 8th Shanghai International Conference on Radiation Oncology. “The Impact of Radiotherapy on Response to Immunotherapy.” Shanghai, China, 8/14/16
12. Leaping Forward Oncology 2017. “Predicting complete response: is there a role for non-operative management of rectal cancer?” Lisbon, Portugal, 5/11/17
13. Australasian Gastrointestinal Trials Group Annual Meeting. “Debate: That complete clinical responders still require surgery for oesophageal cancer.”; “Esophageal cancer and technology-improving the therapeutic ratio.”; “Implementation v Innovation - What rules in my world?” Cairns, Australia, 10/3-10/6/17
14. Royal College of Radiologists, Upper GI Cancer Day, “A US Perspective on the Role of Chemoradiation in Oesophagogastric Cancer.” Cardiff, Wales, 2/9/18
15. International Hepatobiliary Surgery Forum 2018, “The evolving role of radiotherapy for pancreas cancer” and “Stereotactic body radiotherapy for liver tumors”, Hangzhou, China, 6/14-6/16/18
16. Controversies in Clinical Oncology, Tata Medical Center, “SBRT for pancreatic cancer - why, when and how?” “PET-based response evaluation and treatment adaptation in neoadjuvant treatment” and “Selecting patients for radiation therapy in liver oligometastatic disease”, Kolkata, India, 7/5-7/7/18
17. Princess Margaret Cancer Centre Visiting Professor and Radiation Program Rounds Lecture, “Optimizing Efficacy and Minimizing Toxicity in the Treatment of Anal Cancer.” Toronto, ON, 5/17/2019
18. McGill 3rd Annual Upper Gastrointestinal Cancer Symposium, “Locally Advanced Esophageal Adenocarcinoma: Chemoradiation is the Best Treatment,” “Recurrent Esophageal Cancer/Oligometastatic Disease: Role of Local Therapy?” Montreal, Canada, 10/19/19
19. Brazilian Oncology Week, “Radiotherapy and immunotherapy,” “Management of Locally Advanced Esophageal Cancer: Improving the therapeutic ratio,” “Locally advanced rectal cancer with liver and peritoneal metastasis and oligosymptomatic rectal cancer treated with (short) radiation therapy + chemotherapy and simultaneous surgery of the metastases” and “Radiation Therapy: Hypofractionation in rectal cancer: advantages and indications.” Rio de Janeiro, Brazil 10/22/19-10/25/19

20. Indian Society of Oncology, Choosing Wisely in GI Cancers Virtual Symposium. "Role of RTx in neoadjuvant and adjuvant therapy." Virtual Meeting, 8/22/20
21. Tata Memorial Hospital, Mumbai XIX Annual Conference on "Evidence-Based Management of Cancers in India - EBM 2021: Virtual Meeting, "Using Radiation Technology to push the surgical limits for pancreatic cancer." Virtual Meeting, 3/7/21
22. ESMO 23rd World Congress on Gastrointestinal Cancer, "Resectable, Borderline Resectable, and Unresectable Pancreatic Cancer." Virtual Meeting, 6/30/21
23. 12th Shanghai International Conference on Radiation Oncology (SICRO XII), "Role of Radiotherapy in Oligometastatic Colorectal Cancer" Virtual Meeting, 9/11/21
24. 17th World Congress for Esophageal Diseases (ISDE 2021), "Staging, Workup and Decision Making for Locally Advanced Esophageal Cancer" Virtual Meeting, 9/28/21
25. Brazilian Society of Radiotherapy 23rd Congress, "The Role of SABR in Oligometastatic Disease: Past, Present and Future," Virtual Meeting, 11/17/21 – 11/20/21
26. 18th World Congress for Esophageal Diseases (ISDE 2021), "Staging, Workup and Decision Making for Locally Advanced Esophageal Cancer" Virtual Meeting, 9/27/22
27. ESTRO 2023 Annual Meeting, "This house believes that non-metastatic borderline resectable pancreatic cancers should be treated with SBRT: For the Motion." Vienna, Austria, 5/13/23
28. The Royal Australian and New Zealand College of Radiologists Annual Scientific Meeting, "Role of Radiotherapy in Neoadjuvant and Adjuvant Therapy for Pancreas Cancer", "Optimizing Efficacy and Minimizing Toxicity in the Treatment of Anal Cancer", "Management of Locally Advanced Esophageal Cancer: Improving the Therapeutic Ratio", Brisbane, Australia 10/18/23 – 10/21/23.
29. ISDE World Congress for Esophageal Diseases, "PET Directed/Metabolic Directed Treatment: Moving Toward More Tailored Therapy for Esophageal and GEJ Adenocarcinomas," Edinburgh, Scotland, 9/24/2024
30. Israeli Society of Radiation Oncology (ISTRO) First Annual Meeting (Hybrid), "ESOPEC: Impact of the trial on Treatment Decisions in Esophageal Cancer," Tel Aviv, Israel, 10/14/2024 (Remote presentation due to flight restrictions to Israel)
31. 2024 Cambridge Symposium on Oesophageal Cancer, "Optimising Chemoradiotherapy for Patients with Oesophageal Cancer: A Tailored Approach Based On The CALGB 80803 Study," Cambridge, United Kingdom, 11/7/2024
32. British Columbia (BC) Cancer Virtual Academic Forum Updates in GI Cancers: Incorporating the Latest Data into Practice, Virtual Meeting, 3/10/2025

Karyn A. Goodman, MD, MS

MEDIA RESOURCE EDUCATIONAL MATERIALS

ASCO E-learning Courses: 2017 ASCO Annual Meeting: GI Colorectal Highlights, ASCO Annual Meeting Highlights for Radiation Oncology